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ABSTRACT 
Adverse reaction to metal debris (ARMD) represents a recently recognised mode of 
failure of metal-on-metal (MoM) hip resurfacings (HRs) and total hip replacements 
(THRs). ARMD often requires revision surgery which can have poor outcomes, 
therefore questioning the future role of MoM hip bearings. The 14-year survival of 447 
HRs implanted by a designing surgeon was 94.1% (95% CI 84.9%-97.3%) with the best 
outcomes in males with primary osteoarthritis. The 8-year survival of 578 MoM THRs 
was 88.9% (95% CI 78.5%-93.4%) with 44% (17 of 39) of revisions performed for 
ARMD. A systematic review identified six studies reporting short-term outcomes 
following 216 ARMD revisions with variable complication (4%-68%) and re-revision 
(3%-38%) rates. Analysis of outcomes following 64 ARMD revisions demonstrated 
comparable complication (20.3%) and re-revision (12.5%) rates at a mean 4.5 year 
follow-up. The 5-year survival following ARMD revision was 87.9% (95% CI 78.9%-
98.0%) with revision to another MoM bearing having significantly higher re-revision 
rates (p=0.046). Male patients with primary osteoarthritis may undergo HR in the 
future, however designing surgeons may also consider females for HR. There is no 
future role for MoM THR. Limited evidence exists regarding outcomes following 
ARMD revision, though exchange to a non-MoM bearing surface is advised. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Metal-on-metal hip arthroplasty 
Total hip replacement (THR) is well established as the most successful surgical 
procedure for the long-term alleviation of pain and disability in patients with hip joint 
arthritis [1]. Over 75,000 primary THRs were performed in England, Wales, and 
Northern Ireland during 2012 [2]. Metal-on-polyethylene (MoP) bearings were 
traditionally used for THR. The production of polyethylene wear debris can lead to 
periprosthetic osteolysis resulting in aseptic component loosening, which remains the 
most frequent cause of MoP THR failure [3,4]. As bearing wear has been demonstrated 
to be related to usage and not time in-situ [5], MoP THR is a satisfactory option for 
elderly patients with lower demands [6-8]. In contrast, using this bearing surface in 
more active younger patients (under 60 years of age) has been associated with 
unsatisfactory outcomes and high failure rates [9,10].   
 
Over the years metal-on-metal (MoM) bearings have been perceived as an attractive 
option for hip arthroplasty. This type of bearing surface has significantly lower wear 
rates compared to MoP articulations [11]. In addition, larger femoral head sizes can be 
used with MoM bearings compared to MoP. This increases the femoral head-neck ratio, 
which importantly increases hip range of motion, reduces the risk of impingement of the 
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femoral neck on the acetabulum, and reduces the risk of dislocation [12,13]. Therefore 
MoM bearings appear an attractive alternative to MoP articulations in young active 
patients requiring a hip replacement.  
 
Interestingly MoM hip bearings have been around for some time. Although hip 
resurfacing (HR) as recognised today was originally a concept described by Sir John 
Charnley in the 1950s using Teflon-on-Teflon bearings [14], MoM HR was first 
attempted by Edward Haboush in 1953 [15] and Maurice Müller in 1965 [16]. This 
technique failed to gain acceptance and was subsequently abandoned. Further attempts 
at HR during the 1970s by Michael Freeman [17], Heinz Wagner [18], and Harlan 
Amstutz [19] using various combinations of MoP articulation were largely unsuccessful 
compared to conventional THR. This led to HR being temporarily abandoned [20]. 
However it was later observed that some of the MoM HRs originally implanted by 
Müller lasted over 25 years before requiring revision [21]. In addition, the McKee-
Farrar and Ring were two types of large-diameter MoM THR first implanted in the 
1950s to 1960s which demonstrated good long-term outcomes [22,23]. During the late 
1980s Derek McMinn, a surgeon in Birmingham at the time, recognised the promising 
long-term results of MoM THR and considered the poor results observed with earlier 
attempts at HR to be a failure of materials rather than a failure in concept [24]. 
Convinced that MoM bearings were a viable option to treat young and active patients 
with hip arthritis Derek McMinn’s pioneering work during the late 1980’s and early 
1990’s led to the rebirth of modern MoM HR.  
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The technique of modern MoM HR gradually gained acceptance from hip arthroplasty 
surgeons with promising results published at five-years with certain HR devices from 
designing surgeons and independent centres [25-32]. Unique problems related to HR 
prompted the development of large-diameter MoM THRs. First, a device was required 
to manage HR patients with isolated femoral component failure (femoral neck fracture 
or avascular necrosis of the femoral head) occurring in the presence of a well-fixed and 
adequately positioned acetabular component [24,30]. Second, HR is a technically 
demanding procedure for the surgeon with a much steeper learning curve than for 
performing a THR [24-28]. The use of large-diameter MoM THRs would therefore 
allow low volume hip surgeons to obtain the benefits of a MoM bearing for their 
patients but without needing to perform a technically challenging surgical procedure.    
 
Subsequently there was a steep increase in the implantation of MoM hip bearings (HR 
and THR) worldwide. Between 2005 and 2006, 35% of all primary THRs implanted in 
the United States had a MoM bearing [33]. It has been estimated that over one million 
MoM hip arthroplasties have been implanted worldwide [34].  
 
1.2 Adverse reaction to metal debris  
In recent years concerns have mounted regarding abnormal periprosthetic tissue 
reactions associated with MoM hip arthroplasties [35-38]. These reactions can lead to 
early implant failure requiring revision surgery. Numerous terms have been used in the 
literature to describe these abnormal reactions associated with MoM hips [13]. Aseptic 
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lymphocytic vasculitis and associated lesions (ALVAL) was first described in 2005 by 
Willert et al. [39]. ALVAL refers to a specific histological reaction associated with 
MoM hip bearings, which is characterised by perivascular lymphocytes, lymphoid 
aggregates containing follicles with B and T cells, plasma cells, tissue necrosis, fibrin 
exudation, high endothelial venules, and the accumulation of macrophages [39]. In 
2008, Pandit et al. described non-neoplastic, non-infective, solid or semi-liquid soft-
tissue periprosthetic masses associated with MoM HRs, which the authors termed 
“pseudotumours” [35]. Interestingly this term had originally been used in 1987 to 
describe similar periprosthetic tissue reactions to debris released from MoP articulations 
[40]. Although the term “pseudotumour” described a specific clinical problem related to 
MoM hips, it was considered by many to be emotive. In addition, not all patients with 
abnormal reactions have a periprosthetic mass which may be considered to be a 
“pseudotumour.” Therefore this term only accounted for a subset of patients with 
abnormal reactions. In 2010, Langton et al. described the entity “adverse reaction to 
metal debris” (ARMD) [36]. This is now considered the most accepted term in the 
literature [13] and will be used to refer to these abnormal periprosthetic tissue reactions 
associated with MoM hips throughout the thesis. ARMD is an umbrella term, which 
includes both clinical and histological features, namely metallosis (macroscopic soft-
tissue staining associated with abnormal wear), pseudotumour, ALVAL (histological 
diagnosis only), and macroscopic tissue necrosis (observed at revision surgery and 
initial histopathological analysis) [36,41]. ARMD is the sequelae of large amounts of 
metal debris released from MoM hip articulations due to wear and corrosion [42].  
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In theory all MoM hips are at risk of ARMD. However it is becoming increasingly 
apparent the outcomes of MoM hip replacements are dependent on various patient, 
surgeon, and implant factors [13]. Factors associated with an increased risk of 
developing ARMD include female gender, small femoral component sizes in HR, 
malpositioning of the acetabular component, and patients with hip dysplasia [36,41,43-
45]. In addition, it appears the risk of ARMD is greater in THRs compared to HRs given 
that additional metal wear debris can be generated at the taper-head interface and other 
modular junctions [2,37,38]. This is supported by clinically significant differences in 
short-term failure rates for MoM THRs (48.8% at six-years) and HRs (25% at six-years) 
with identical bearing surfaces produced by the same manufacturer [38].   
 
The subsequent local tissue reactions can result in the formation of destructive soft-
tissue masses often requiring revision surgery [35]. At the time of revision findings can 
include significant bone loss and muscle damage [35,36]. Limited evidence exists 
regarding clinical outcomes following ARMD revision surgery, however this suggests 
short-term outcomes are poor with a number of patients experiencing recurrence of these 
lesions and requiring further surgery [46]. These unsatisfactory outcomes are concerning 
given most MoM hip patients are young and active [25-32]. Furthermore in England, 
Wales, and Northern Ireland the prevalence of ARMD revision surgery is increasing 
with ARMD accounting for 13% (n=1,330) of all revisions performed in 2012 [2]. 
 
In light of MoM hips developing ARMD in recent years the Medical and Healthcare 
Products Regulatory Agency (MHRA) have withdrawn certain devices with 
unacceptably high failure rates and issued guidance regarding the investigation and 
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management of these periprosthetic reactions [47,48]. There has subsequently been a 
significant decrease in MoM hip usage worldwide. In England, Wales, and Northern 
Ireland, MoM THR and HR once accounted for 10.9% and 10.8% of all primary THRs 
performed respectively [2]. By contrast in 2012 MoM THR and HR accounted for 0.1% 
and 1.3% of all primary THRs performed respectively [2]. 
 
1.3 Research rationale  
Despite the increasing awareness regarding ARMD over the last five-years a number of 
reports have subsequently confirmed earlier results regarding HR [25-32]. Specifically 
good ten-year outcomes have been achieved by designing and independent surgeons in 
certain patient subgroups when using HR implants with an established record [49-54]. 
This suggests select patients will benefit from MoM HR and if these subgroups can 
clearly be identified these patients could be considered for HR in the future. However 
long-term follow-up studies into the second decade and particularly in younger patient 
populations are still lacking. In contrast evidence currently suggests MoM THR should 
not be used in the future [55], though not all MoM THR designs have results published 
from independent centres.    
 
Due to the more intense clinical surveillance and investigations recommended for 
patients with MoM hip arthroplasties it is expected the number of patients requiring 
revision surgery for ARMD will continue to increase [2,48]. Although there is limited 
evidence currently available [46] it is important that surgeons are aware of the likely 
clinical outcomes following ARMD revision surgery. This will allow patients to be 
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more effectively counselled regarding the risks of undergoing such surgery. Given 
ARMD has been observed in a number of asymptomatic MoM hip patients [56,57] it is 
expected improved awareness of the risks of revision surgery may be of increasing 
importance when counselling these individuals. In addition, only one study has 
examined factors affecting outcome following ARMD revision [58]. Determining 
prognostic factors of outcome following ARMD revision is important as this will help 
identify the thresholds for performing revision surgery.  
 
1.4 Research objectives 
1. To determine the long-term clinical outcomes following primary metal-on-metal 
hip resurfacing and explore factors affecting outcomes.   
2. To determine the medium-term clinical outcomes following primary metal-on-
metal total hip replacement.  
3. To determine the clinical outcomes following revision of metal-on-metal hip 
resurfacings and total hip replacements for adverse reaction to metal debris and 
identify factors predictive of clinical outcomes. 
 
1.5 Structure of the thesis  
The thesis will initially describe two prospective cohort studies which assess the long-
term clinical outcomes following MoM HR (Chapter 2) and the medium-term clinical 
outcomes following MoM THR (Chapter 3). Outcomes following revision of MoM HRs 
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and THRs for ARMD will be assessed using a systematic review (Chapter 4) followed 
by a retrospective cohort study (Chapter 5) with the latter also exploring factors 
predictive of outcomes. Finally the important findings and conclusions of the work 
presented will be summarised and considered in the context of the present literature, 
with recommendations for future research proposed (Chapter 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
9	  
	  
CHAPTER 2 
LONG-TERM OUTCOMES OF METAL-ON-METAL HIP RESURFACING 
 
2.1 Declaration 
The work detailed in this chapter has been published in a peer reviewed journal. As first 
author of this work my role involved input with study design, data collection including 
all radiographic analysis, involvement with statistical analysis and data interpretation, 
and the writing of all versions of the paper submitted to the journal as well as this 
chapter.  
 
Matharu GS, McBryde CW, Pynsent WB, Pynsent PB, Treacy RB. The outcome of the 
Birmingham Hip Resurfacing in patients aged < 50 years up to 14 years post-
operatively. The Bone and Joint Journal 2013; 95(9): 1172-1177.  
 
2.2 Introduction 
The long-term survival reported for conventional THR in young and active patients with 
hip arthritis has been unsatisfactory [9,10,59,60]. A report from the Finnish 
Arthroplasty Register on 3668 THRs implanted in patients under 55 years of age 
highlights this problem, with a 15-year survival of 71% for cemented implants, and as 
low as 58% for some uncemented THRs [10].   
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Resurfacing of the hip is a recognised treatment for young and active patients with 
painful primary or secondary hip joint arthritis [50]. The Birmingham Hip Resurfacing 
(BHR; Smith & Nephew, Warwick, United Kingdom) was introduced in July 1997 and 
remains one of the most commonly used MoM HR devices with an estimated 125,000 
implanted worldwide [61]. The BHR is produced from an as-cast high carbon cobalt-
chromium-molybdenum alloy (Figure 2.1) [24]. The actetabular component is 
hemispherical with a hydroxyapatite coating which allows uncemented fixation. 
Component sizes range from 44 mm to 66 mm (available in 2 mm increments) for the 
acetabular implant. The femoral component requires cement for fixation and is available 
in sizes from 38 mm to 58 mm (available in 2 mm increments). For the BHR the 
acetabular component implanted must always be 6 mm or 8 mm larger than the femoral 
component used. 
 
Figure 2.1 The Birmingham Hip Resurfacing 
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Despite concerns regarding MoM hips developing ARMD (Chapter 1.2), good clinical 
outcomes have been reported for the BHR at up to ten-years by both the designing 
surgeons [50,51] and independent centres [52-54]. It is also becoming apparent that 
females and patients with small femoral component head sizes are factors associated 
with higher failure rates in HR [44,50,52-54].      
 
The study aims were to determine the long-term survival and functional outcome of 
primary BHR in a large cohort of patients less than 50 years of age at operation, and to 
explore factors affecting outcome. 
 
2.3 Methods  
 
2.3.1 Study design and patient cohort 
Between August 1997 and April 2006, data were prospectively collected on all 
consecutive BHRs (447 hips in 393 patients) implanted in patients under 50 years of age 
(Table 2.1). All operations were performed by one designing surgeon at a specialist 
arthroplasty centre (The Royal Orthopaedic Hospital, Birmingham). Information 
regarding patient selection and operative technique for the BHR has previously been 
described in detail [50,62]. Briefly patients with end-stage hip arthritis were considered 
suitable candidates for BHR if they were under the age of 65 years, maintained an active 
lifestyle which included sports participation, and had normal bone stock on pre-
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operative pelvic radiographs.  All operations were performed in a clean-air laminar flow 
operating theatre using a posterior surgical approach to the hip joint [27,63]. 
 
Table 2.1 Summary of the study cohort 
Characteristic  Study cohort (n=447 hips) 
Gender Male  
Female 
267 (59.7%) 
180 (40.3%) 
Age Mean (range) in years 41.5 (14.9 to 49.9) 
Bilateral hips Total patients  
Single-stage bilateral procedures 
Two-stage bilateral procedures 
54 (108 hips) 
15 (30 hips) 
39 (78 hips) 
Diagnosis Primary osteoarthritis 
Developmental dysplasia 
Avascular necrosis 
Inflammatory arthritis 
Slipped upper femoral epiphysis 
Other causes 
304 (68.0%) 
46 (10.3%) 
41 (9.2%) 
21 (4.7%) 
13 (2.9%) 
22 (4.9%) 
Follow-up time Mean (range) in years  10.1 (5.2 to 14.7) 
Femoral component 
size 
38 mm 
42 mm 
46 mm 
50 mm 
54 mm 
58 mm 
3 (0.7%) 
47 (10.5%) 
125 (28.0%) 
169 (37.8%) 
92 (20.6%) 
11 (2.5%) 
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2.3.2 Data collection and follow-up after BHR 
Data were extracted from the institution’s prospectively maintained database (MySQL 
database, Oracle Corporation, Redwood Shores, California). The database contains a 
vast amount of information including patient demographics, primary indication for 
surgery, and component sizes implanted. This study was approved and registered with 
the relevant hospital department.  
 
A number of methods were used to determine the final outcome of the BHR [64]. The 
surgeon’s routine practice was to review patients at six-weeks post-operatively in the 
out-patient clinic, and thereafter at an invitational annual clinical review. All 
consultations included clinical examination, anteroposterior pelvic radiographs, and 
completion of the Oxford Hip Score (OHS) questionnaire [27,50]. The OHS is a 
commonly used patient-reported outcome measure assessing pain and disability 
following hip arthroplasty which has been demonstrated to be a reliable, responsive, and 
valid outcome measure [65]. In addition, all patients were sent a postal questionnaire 
(detailed below). The questionnaire was sent up to four times to any non-responding 
patients. Those failing to respond to all postal questionnaires were subsequently 
contacted by telephone to complete data collection.   
 
The questionnaire requested details on any further surgical intervention, including 
revision, the patient may have had on the ipsilateral hip (Appendix 1). If revision was 
performed, details of the location of the surgery, the revision indication, and the 
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findings at surgery were obtained from the treating surgeon or hospital. As part of the 
questionnaire patients were asked to complete the OHS [65] (Appendix 2) and the 
University of California, Los Angeles (UCLA) Activity Score [66] (Appendix 3).  
 
All deaths occurring during the study period were recorded. In each case assessment 
was made using the patient case notes and details held by the general practitioner to 
identify whether the death was related to the BHR surgery, and whether the hip had 
been revised or remained in-situ at the time of death.  
 
Consideration was given to obtaining study data from the NJR. Given all primary and 
revision hip arthroplasty procedures should be recorded in the NJR, registry data has the 
advantage of capturing revisions performed at other centres. However, the institutional 
database was considered more appropriate given the study aims were to determine the 
long-term outcomes of BHRs performed between August 1997 and April 2006. The 
NJR commenced in April 2003 with poor compliance and procedure linkability reported 
in the early years [2]. Although patient reported outcome measure scores are collected 
nationally at six-months following primary hip replacement, a recent study observed 
significant changes occur in these scores during the first twelve-months following hip 
arthroplasty [67]. Using the institutional database therefore has the advantage of 
obtaining serial functional outcome scores at long-term follow-up [67]. 
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2.3.3 Functional outcomes 
The OHSs were expressed as a percentage (healthy joint scoring 0% and worst possible 
joint 100%) with questionnaires considered valid if they met the minimum inclusion 
criteria previously described [68,69]. As the OHS is currently most commonly scored in 
the literature on a scale of 0 to 48 points (0 being the worst possible joint and 48 
representing a healthy joint) [70], these scores have also been provided to assist 
comparison with other reports. However, the percentage method used at this institution 
includes methods for dealing with missing and multiple responses to questions [68], 
therefore direct conversion to an OHS on the 48-point scale may not be completely 
representative. Pre-operative OHSs for the cohort were also available for analysis. The 
UCLA activity score ranged from 1 (wholly inactive) to 10 (regular participation in 
impact sports).   
 
2.3.4 Radiological analysis 
All pelvic radiographs available at the time of most recent follow-up were analysed for 
signs suggestive of implant failure. The femoral component was considered to have 
evidence of loosening if there was a radiolucent line > 2 mm in any of the three zones 
described by Amstutz et al. [25]. Acetabular loosening was defined as a radiolucent line 
> 2 mm in two or more zones as described by DeLee and Charnley [71]. Any osteolysis 
around the femoral or acetabular components was recorded. Acetabular component 
inclination and femoral stem-shaft angles were measured as previously described [72].  
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2.3.5 Statistical analysis 
All statistical analysis was performed using the program R (R Foundation for Statistical 
Computing, Vienna, Austria) [73]. Cumulative BHR survival was determined using the 
Kaplan–Meier method, with the Peto method used to calculate the lower 95% 
confidence interval (CI) [74]. The endpoint for survival analysis was revision surgery, 
defined as removal or exchange of either the femoral or acetabular component, or both. 
Patients not undergoing revision surgery were censored after their last contact with the 
hospital, whether it was in clinic or by completion of the postal or telephone 
questionnaire, or after death.  
 
A Cox-proportional hazards model was used to compare the differences in BHR 
survival distributions for each of the covariates recorded [75]. A multivariate model was 
constructed, and then covariates that were not significantly influential were 
systematically removed from the model to identify those having the greatest influence 
on survival. A Mann-Whitney test was used to compare functional outcomes (OHS and 
UCLA score) between males and females. A Shapiro-Wilk test was performed on the 
relevant data to test for normality, and where appropriate the median and interquartile 
range (IQR) were used rather than the mean and range. The level of significance was set 
at 95% (p<0.05) and CIs were also at the 95% level.   
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2.4 Results  
 
2.4.1 Survival analysis and factors affecting survival  
The final outcome of the BHR was obtained in all patients during this study, with no 
patient lost to follow-up. There were 11 patient deaths (13 hips), all unrelated to BHR 
surgery, and none of these patients underwent implant revision. A total of 16 BHRs 
(3.6%) in 15 patients were revised (Table 2.2) at a mean of 6.2 years (range 0.5-11.8 
years) from primary BHR. All revisions were performed at this institution with some 
described in detail previously [27,50]. Excluding revisions, no patient underwent any 
further surgical interventions on the ipsilateral BHR. 
 
Table 2.2 Details of 16 Birmingham Hip Resurfacings requiring revision surgery 
 
Revision Sex Age (years) 
Primary 
diagnosis 
Femoral 
head 
size 
(mm) 
Time to 
revision 
(years) 
Revision 
indication 
1 F 49 OA 46 0.5 
Aseptic 
acetabular 
loosening 
2 M 44 OA 54 0.5 Deep infection 
3 F 49 OA 42 0.7 Neck fracture 
4 F 49 OA 46 1.8 Undiagnosed pain 
5 F 48 OA 46 2.2 Deep infection 
6 F 43 OA 42 5.3 Deep infection 
7 M 42 AVN 50 5.9 Aseptic femoral loosening 
8 F 26 DDH 42 6.3 
Aseptic femoral 
loosening 
9 F 42 OA 42 6.7 Aseptic femoral 
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loosening 
10 M 30 RA 46 7.1 Undiagnosed pain 
11 F 17 Inflammatory arthritis 42 9.4 
Aseptic femoral 
loosening 
12 M 30 AVN 50 9.5 
Aseptic femoral 
loosening 
13 F 17 AVN 42 9.9 AVN 
14 F 49 OA 50 10.2 Undiagnosed pain 
15 F 36 OA 46 10.8 Implant fracture 
16 M 43 Perthe’s 50 11.8 Aseptic femoral loosening 
  
AVN = avascular necrosis of the femoral head; DDH = developmental dysplasia of the 
hip; F = female; M = male; OA = osteoarthritis; RA = rheumatoid arthritis  
Revisions number 1 and 5 were performed in the same patient who had bilateral hip 
resurfacings. 
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The cumulative survival rate for all BHRs (n=447) at 10-years was 96.3% (95% CI 
93.7%-98.3%; 202 hips at risk) and at 14-years was 94.1% (95% CI 84.9%-97.3%; 23 
hips at risk) (Figure 2.2).  
 
Figure 2.2 Kaplan-Meier survival curve for all Birmingham Hip Resurfacings (n=447) 
 
Revision for any indication was used as the endpoint for survival, with 16 hips revised 
in total. Shaded area represents the upper and lower limits of the 95% confidence 
intervals. 
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The cumulative survival for 195 BHRs implanted in males with primary osteoarthritis 
and aseptic revision used as the endpoint was 100% (95% CI 100%-100%) at both 10-
years (89 hips at risk) and 14-years (16 hips at risk), with no hips requiring revision 
(Figure 2.3).  
 
Figure 2.3 Kaplan-Meier survival curve for Birmingham Hip Resurfacings implanted in 
males for primary osteoarthritis with aseptic revision as the endpoint (n=195) 
 
 
No aseptic revisions were performed during follow-up. 
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The cumulative survival for 109 BHRs implanted in females with primary osteoarthritis 
and aseptic revision used as the endpoint was 96.1% (95% CI 90.1%-99.9%; 52 hips at 
risk) at 10-years and 91.2% (95% CI 68.6%-98.7%; 6 hips at risk) at 14-years (Figure 
2.4), with six hips requiring revision.  
 
Figure 2.4 Kaplan-Meier survival curve for Birmingham Hip Resurfacings implanted in 
females for primary osteoarthritis with aseptic revision as the endpoint (n=109) 
 
 
 
Shaded area represents the upper and lower limits of the 95% confidence intervals. 
There were six aseptic revisions performed during follow-up. 
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Females had a significantly increased risk of revision over males (p=0.047). Decreasing 
femoral head size was significantly associated with an increased risk of revision 
(p=0.044) (Figure 2.5). 
 
Figure 2.5 Kaplan-Meier survival curve for Birmingham Hip Resurfacings in relation 
to femoral head size with aseptic revision as the endpoint (n=447) 
 
Femoral head size given in millimetres. Confidence intervals have not been included for 
clarity. The survival for femoral head sizes 58, 54 and 38 overlap at a cumulative 
proportion surviving level of 1.00, as no aseptic revisions occurred in these three 
femoral head size groups. 
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The designing surgeon has performed over 4000 BHRs to date. To assess the validity of 
the survival data obtained from the institutional database, the designing surgeon has 
provided a survivorship funnel plot based on NJR data. This plot compares his BHR 
results to other surgeons implanting any MoM hip device (Figure 2.6). The NJR data 
confirms the designing surgeons exceptional survival results for all BHRs implanted, 
with the surgeon lying more than three standard deviations (>99.8%) from his peers.  
 
Figure 2.6 National Joint Registry standardised revision ratio funnel plot for all metal-
on-metal hip procedures (including hip resurfacing) 
 
 
Figure kindly reproduced courtesy of Mr Ronan Treacy. Funnel plot produced on the 
17th March 2015 and includes NJR data from April 2003 to December 2014. The plot 
confirms the surgeons’ excellent survival results with hip resurfacing which correlate 
well with the outcomes recorded in the institutional database. 
24	  
	  
2.4.2 Functional outcomes  
The median OHS was 60% (IQR 46%-73%) pre-operatively and 4.2% (IQR 0%-24%) 
at latest follow-up. Using the 48-point OHS, this equated to a median pre-operative 
OHS of 19.2 (IQR 13.0-25.9) which improved to 46.0 (IQR 36.5-48.0) at latest follow-
up. Males had significantly better OHSs than females (median 3.1% (46.5/48) vs. 6.3% 
(45.0/48); p=0.02). The median UCLA score was 6.0 (IQR 5-8) at latest follow-up, with 
males scoring significantly higher than females (median 7.0 vs. 5.0; p=0.01).  
 
2.4.3 Radiological analysis 
At the time of BHR the mean acetabular component inclination angle for the cohort was 
47.1° (range 31°-67°) as measured from the initial post-operative radiographs, and the 
mean femoral stem–shaft angle was 138.6° (range 125°-152°). Pelvic radiographs were 
available for review at the time of latest follow-up in 196 of the 431 hips (45%) not 
requiring BHR revision surgery. In these follow-up radiographs there was no change in 
the acetabular component inclination angle (mean 48.2°; range 31°-67°) or the femoral 
stem–shaft angle (mean 138.8°; range 126°-152°) from the initial post-operative 
radiographs. None of the radiographs available at the time of latest follow-up 
demonstrated any evidence of osteolysis, loosening of the femoral or acetabular 
components, or any femoral neck thinning. 
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2.5 Discussion  
The study findings demonstrate that the BHR provides excellent survival and functional 
results in young males with primary osteoarthritis into the second decade, with good 
survival achieved in appropriately selected female patients. With no patient loss to 
follow-up, overall BHR survival was 94.1% (95% CI 84.9%-97.3%) at 14-years (Table 
2.3). 
 
Table 2.3 Comparison of the present study results with independent series reporting 
ten-year survival of the Birmingham Hip Resurfacing 
 Present 
study 
Coulter et al. 
[52] 
Holland et al.  
[53] 
Murray et al.  
[54] 
BHRs (n) 447 230 100 646 
Patients (n) 393 213 90 554 
Mean age 
(range) in years 
41.5  
(14.9-49.9) 
52.1  
(18-82) 
51.3  
(21-68) 
51.9  
(16.5-81.5) 
Male (n) 59.7% (267) 66% (140) 74% (74) 59% (379) 
Primary 
osteoarthritis 
(n) 
68% (304) NS  79% (79) 81% (526) 
Mean (range) 
follow-up time 
in years  
10.1  
(5.2-14.7) 
10.4  
(9.6-11.7) 
9.6  
(0.2-13) 
8.0  
(1-12) 
BHRs lost to 
follow-up (n) 
0% (0) 7% (16) 2% (2) 2% (12) 
Overall survival 
10-year 
14-year 
 
96.3%  
94.1% 
 
94.5% 
NS 
 
92% 
NS 
 
87.1% 
NS 
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BHRs revised 
(n) 
3.6% (16) 4.8% (11) 8% (8) 8.4% (54) 
BHR revision 
vs. Female 
gender  
p=0.047 p=0.019 p=0.240 Not significant 
(value not 
stated) 
BHR revision 
vs. Decreasing 
femoral head 
size   
p=0.044 p=0.123 p=0.030 p=0.030 
 
BHR = Birmingham Hip Resurfacing; NS = not reported                             
 
Recent reports from independent centres have demonstrated good survival for the BHR 
at ten-years [52-54], which are comparable to that reported by the designing surgeons 
[50,51]. HR is recognised as a more technically demanding procedure for surgeons than 
conventional THR [76], therefore the reproducibility of 10-year results from 
independent centres is encouraging. The present study provides the longest reported 
survival of the BHR prosthesis in young patients and is comparable to that reported 
from another designing surgeon series of 96% at 13-years [51]. Although the present 
long-term survival results compare favourably to registry reports detailing long-term 
THR survival in young patients with traditional MoP bearings [10], ceramic-on-ceramic 
(CoC) bearings are beginning to show promise [77]. Two recent studies have reported 
10-year survival rates of 95.6% (n=218; mean age 60 years) [78] and 97.9% (n=73; 
mean age 55 years) [79] with CoC THR, which are comparable to the present results. 
Although this THR bearing may appear attractive in treating young patients, it is 
recommended longer term follow-up studies are performed in larger and younger 
patient cohorts to define the role of CoC THR in this patient population.         
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In recent years accelerated failure of some MoM hip implants have been reported 
(Chapter 1.2). However no revisions for ARMD were performed in the present study. In 
addition, no patient in this series is currently under investigation for a painful BHR with 
suspected ARMD. It is worth considering this study comprised of a very young patient 
cohort (mean age 41.5 years) compared to previous studies (mean age of 48.3-53.0 
years) [26,51-54]. These young active patients with hip arthritis have traditionally been 
difficult to treat, with unsatisfactory long-term outcomes with conventional THR 
[9,10,59,60]. The findings from this study therefore support the continued use of the 
BHR in this patient population, provided they meet the other selection criteria for HR 
[50,62].     
  
Young male patients undergoing BHR for primary osteoarthritis were the best 
performing subgroup, with only one revision for deep infection and 100% survival at 
14-years with aseptic revision as the endpoint. These excellent results are comparable to 
a recent independent report demonstrating a 10-year BHR survival of 99% in males 
under 50 years of age with primary osteoarthritis [54]. In contrast, the results of HR in 
females have proved to be more controversial.  
 
Two recent independent studies have reported significantly inferior survival in females 
compared to males at 10-years following BHR, and therefore have recommended 
against performing HR in females [52,54]. Indeed, our previously reported experience 
[27] and findings from this study similarly demonstrate significantly better survival in 
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males. However the inferior survival reported in females is likely to be complex and 
multifactorial [69]. Female patients usually require smaller implants, and both this study 
and previous reports have demonstrated increased failure rates with decreasing femoral 
component head sizes [50,52-54,69]. The present study findings at long-term follow-up 
(Figure 2.5) confirm the earlier work of McBryde et al., which demonstrated that 
femoral head size was the best predictor of revision in 2123 BHRs at a mean of 3.5 
years follow-up [69]. In addition, young women more commonly have hip dysplasia, 
and such pathology has been demonstrated to be associated with a relatively inferior 
survivorship [51]. In this study, of the 16 revised hips 7 (44%) were in patients with 
diagnoses other than primary osteoarthritis, although only 143 (32%) of all BHRs were 
implanted for these indications. More recently, observations from independent centres 
have suggested females are at increased risk of ARMD with certain MoM hip implants, 
which has led to many surgeons avoiding performing HR in women [36,44,54]. Taking 
all of this into account the present study demonstrated that in females under 50 years of 
age with primary osteoarthritis and aseptic revision used as the endpoint, cumulative 
survival was 96.1% at 10-years and 91.2% at 14-years. This is well within the 
acceptable limits quoted in published guidelines from the National Institute for Health 
and Clinical Excellence (NICE), which recommends a revision rate of 10% or less at 
10-years for continued implant usage [80]. These results also exceed the long-term 
survival reported by registries following THR in a similar young patient group [10]. In 
light of this, we support the continued use of the BHR in young women, provided they 
have primary osteoarthritis, have adequate femoral anatomy to allow the use of a 
femoral head size of typically above 46 mm, and meet all the other established 
indications for HR [50,62].    
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The functional outcome following BHR for this cohort was excellent. At latest follow-
up the majority of patients were almost completely asymptomatic, with a median OHS 
of 4.2% (or 46/48) and the 25th percentile scoring 0% (or 48/48). These results are 
similar to both our previously reported findings [50,69] and those from other centres 
[52,54]. In an earlier analysis including 2123 BHRs significant improvement in the 
OHS was observed for the first 12-months post-operatively, with the score maintained 
for the duration of follow-up [69]. As the OHS may not have a sufficiently demanding 
scale to reveal limitations in very active patients, the UCLA score was also used which 
demonstrated levels of function similar to those previously reported after BHR [50,52-
54].  
 
This study has some recognised limitations. This consecutive series was performed by 
one designing HR surgeon with excellent BHR survival confirmed by independent NJR 
data (Figure 2.6), therefore the results achieved may not be reproducible when the 
surgery is performed by others. However the series includes the surgeon’s learning 
experience with this implant and also spans a period when subtle nuances of 
anteversion, combined anteversion, and aiming for an acetabular inclination of under 
450 were not fully appreciated when performing HR [81], some of which may have been 
responsible for early failures. Radiographic analysis at latest follow-up was not possible 
for a number of hips as not all patients attended for clinical review. They were instead 
assessed using questionnaires. Therefore despite determining the final implant outcome 
in all patients as well as obtaining functional outcome scores, it remains possible some 
30	  
	  
hips may have radiological evidence suggestive of implant failure. Other studies 
reporting 10-year BHR survival have similarly encountered difficulties in obtaining 
complete radiological review [52,54]. However it is established that survival analysis 
into the second-decade is important to determine the long-term outcomes of any implant 
[82], and as such this study adds valuable information to the literature regarding the 
BHR. Blood metal ion levels and cross-sectional implant imaging were not routinely 
available for analysis in this cohort, as these investigations are not required in 
asymptomatic patients with well-functioning HRs [48]. Such investigations would have 
allowed an assessment of component wear to be made.  
 
In conclusion, this designing surgeon series has demonstrated that the BHR provides 
excellent survival and functional results into the second decade in males under 50 years 
of age with primary osteoarthritis. Good survival was also achieved in appropriately 
selected young females, and was within the recommended thresholds proposed by NICE 
even at 14-years. It is therefore recommended the BHR can be used in females with 
primary osteoarthritis and an adequately sized femoral head, provided they fulfill all the 
other established indications for HR.  
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CHAPTER 3 
MEDIUM-TERM OUTCOMES OF METAL-ON-METAL                           
TOTAL HIP REPLACEMENT  
 
3.1 Declaration 
The work detailed in this chapter has been published in a peer reviewed journal. As first 
author of this work my role involved input with study design, data collection including 
all radiographic analysis, involvement with statistical analysis and data interpretation, 
and the writing of all versions of the paper submitted to the journal as well as this 
chapter.  
 
Matharu GS, Theivendran K, Pynsent PB, Jeys L, Pearson AM, Dunlop DJ. Outcomes 
of a metal-on-metal total hip replacement system. Annals of The Royal College of 
Surgeons of England 2014; 96(7): 530-535.  
 
3.2 Introduction 
The use of MoM bearings in THR has been considered an attractive option for treating 
young active patients with hip joint arthritis given the lower wear rates of MoM 
bearings compared to MoP (Chapter 1.1). This resulted in an increased usage of large-
diameter MoM hip bearings during the last decade with over one million MoM hips 
implanted worldwide [34]. Recently reports have observed high short-term failure rates 
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due to ARMD for a number of MoM THR designs (Chapter 1.2). This has led to the 
MHRA issuing guidance regarding the investigation and management of MoM hip 
patients, the withdrawal of devices with unacceptably high failure rates, and a 
significant decrease in MoM hip usage worldwide [2,47,48].   
 
The study aims were to determine the medium-term clinical outcomes for one 
commonly used primary MoM THR system. Outcomes of interest were implant 
survival, function, blood metal ion concentrations, and radiological analysis.  
 
3.3 Methods 
 
3.3.1 Study design and patient cohort 
Between January 2004 and December 2010, data were prospectively collected on all 
consecutive MoM THRs (578 hips in 511 patients) implanted at one specialist 
arthroplasty centre (The Royal Orthopaedic Hospital, Birmingham). All MoM THRs 
consisted of the Corail femoral stem and the Pinnacle acetabular component (both 
manufactured by DePuy Ltd, Leeds, United Kingdom). Since 2010 this MoM THR 
system has not been implanted due to reports of high failure rates with similar implants 
and various device recalls [37,38,47,48]. Patients were selected for MoM THR if they 
had end-stage hip arthritis and wished to maintain a reasonably active lifestyle. All 
operations were performed in a clean-air laminar flow operating theatre by ten surgeons 
with three surgeons performing the majority (n=459; 79.4%). Data on patient 
33	  
	  
demographics, primary indication for THR, and components implanted were extracted 
from the institution’s prospectively maintained database (Table 3.1). This study was 
approved and registered with the relevant hospital department.  
 
Table 3.1 Summary of the study cohort 
Characteristic  Study cohort  
(n= 578 hips) 
 
Gender Female  
Male 
 340 (58.8%) 
 238 (41.2%) 
 
Age Mean (range) in years 60.0 (19.8-88.0) 
 
Bilateral hips Total patients  
Single-stage bilateral procedures 
Two-stage bilateral procedures 
67 (134 hips) 
1 (2 hips) 
66 (132 hips) 
 
Diagnosis Primary osteoarthritis 
Developmental dysplasia 
Avascular necrosis 
Inflammatory arthritis 
Neck of femur fracture 
Slipped upper femoral epiphysis 
Other causes 
533 (92.2%) 
12 (2.1%) 
10 (1.7%) 
5 (0.9%) 
5 (0.9%) 
3 (0.5%) 
10 (1.7%) 
 
Follow-up time Mean (range) in years   5.0 (1.0-9.1) 
 
Surgical approach Posterior 
Anterolateral  
537 (92.9%) 
41 (7.1%) 
 
Grade of surgeon Consultant 
Specialist registrar 
559 (96.7%) 
19 (3.3%) 
 
Femoral head size 28 mm 
36 mm 
14 (2.4%) 
564 (97.6%) 
 
Acetabular 
component size 
Median 
Range 
52 mm 
48-66 mm 
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Figure 3.1 The Corail, Pinnacle, Ultamet metal-on-metal total hip replacement system 
 
 
3.3.2 Implant design 
The Corail femoral stem is a fully hydroxyapatite coated titanium alloy stem designed 
for insertion without cement (Figure 3.1). The stem is available in a range of sizes (6-
20) with all but the smallest sizes available with either a collar or collarless option. 
Three different options of neck geometry are available (standard, high offset, and coxa 
vara) but the neck itself is not modular. All stem options have a 12/14 taper onto which, 
in this series, a 36 mm or 28 mm diameter cobalt chromium alloy metal femoral head 
(Articul/eze, DePuy Ltd, Leeds, United Kingdom) was impacted. The Pinnacle 
acetabular component is a hemispheric porous-coated titanium shell which is inserted 
without cement and can accommodate a polyethylene, ceramic, or metal liner (Figure 
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3.1). In this series metal liners were used (Ultamet, DePuy Ltd, Leeds, United 
Kingdom). The acetabular component is available in a range of diameters (38-66 mm) 
and includes solid backed, spiked solid back, three-hole, and multi-hole cup varieties.  
 
Similar to most other large-diameter MoM THRs, the Corail, Pinnacle, Ultamet MoM 
THR system has three interfaces: (1) stem taper and femoral head, (2) femoral head and 
acetabular liner, and (3) acetabular liner and acetabular component. By contrast, MoM 
HR devices do not have a modular femoral head or acetabular liner. Therefore the only 
interface in HRs is the single articulation between the femoral and acetabular 
components (Figure 2.1).    
 
3.3.3 Data collection and follow-up after THR 
Patients underwent clinical review at six-weeks, six-months, and one-year post-
operatively with invitations for annual clinical review thereafter. All consultations 
included clinical examination, anteroposterior pelvic radiographs, and completion of the 
OHS questionnaire [65]. After the 2010 MHRA alert which highlighted concerns 
regarding ARMD associated with MoM hip replacements [47] all patients with MoM 
THRs were recalled to this institution for clinical review and blood metal ion sampling 
(Appendix 4). In line with MHRA recommendations, cross-sectional periprosthetic 
imaging was performed in all symptomatic patients and any asymptomatic patients with 
high blood metal ion concentrations [48]. Patients with high blood metal ion 
concentrations and periprosthetic effusions on further imaging were considered to have 
ARMD. ARMD was subsequently confirmed intra-operatively at revision and after 
histopathological analysis.      
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Data were collected on all revision THR surgery performed up until 31st October 2013 
with details obtained from other hospitals if revisions were performed elsewhere. Data 
from the NJR was also used to confirm no revisions performed elsewhere were missed. 
All deaths were recorded and assessed as previously described (Chapter 2.3.2). 
 
3.3.4 Blood metal ion sampling 
Blood metal ion sampling was performed at a minimum of one-year following 
arthroplasty to avoid taking measurements during the running-in phase [83]. Whole 
blood was obtained from each patient with cobalt and chromium concentrations 
measured using inductively-coupled plasma mass spectrometry as previously described 
[84]. Whole blood metal ions were considered raised if cobalt and/or chromium 
concentrations were greater than 7 µg/l as per MHRA recommendations [48].   
Although the stem is made of titanium alloy, titanium concentrations were not measured 
because this is not recommended in the current MHRA guidelines [48]. Other authors 
have measured blood titanium concentrations in non-MoM THR patients with well-
functioning hips [85], and in patients with failure due to corrosion at the femoral head-
neck taper requiring revision surgery [86]. Interestingly both patient groups had low 
blood titanium concentrations [85,86] suggesting this particular metal ion may not be 
useful for identifying failing MoM THRs.  
 
3.3.5 Functional outcomes and radiological analysis 
The OHS questionnaire (Appendix 2) was used to assess pain and disability before and 
after MoM THR [65]. This questionnaire was scored as already described (Chapter 
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2.3.3). All anteroposterior pelvic radiographs available at the time of most recent 
follow-up were analysed for signs suggestive of implant failure. Analysis of radiographs 
was performed as previously described (Chapter 2.3.4), which included assessing the 
femoral stem for evidence of component loosening [87] or subsidence [88]. 
 
3.3.6 Statistical analysis 
All statistical analysis was performed using the program R [73]. Cumulative implant 
survival analysis and Cox-proportional hazards modelling was performed as described 
earlier (Chapter 2.3.5). Mood’s test was used to compare OHSs between males and 
females. The level of significance was set at 95% (p<0.05) and CIs were also at the 95% 
level.   
 
3.4 Results  
 
3.4.1 Survival analysis   
All patients were reviewed following the institutions recall therefore no patient was lost 
to follow-up. The mean follow-up time since index THR was 5.0 years (range 1.0-9.1 
years) with 92% (529 of 578 THRs) having a minimum follow-up of three-years. There 
were 22 patient deaths (22 hips) during follow-up which occurred at a mean of 2.7 years 
(range 1.4-6.5 years) from the index procedure. All deaths were unrelated to surgery.  
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During follow-up 39 hips (6.7%) in 38 patients underwent revision surgery (Table 3.2) 
with all revisions performed at this institution. All 39 hips revised had an initial femoral 
component head size of 36 mm. Mean time from index THR to revision arthroplasty 
was 3.5 years (range 0.01-8.3 years) with 30 revisions (77%) performed in females. 
 
Table 3.2 Clinical details of the 39 revised metal-on-metal total hip replacements 
Revision Age 
(years) 
/ sex 
Time to 
revision 
(years) 
Cup 
size 
(mm) 
Primary 
indication  
Revision 
indication 
Revision     
bearing 
Operative         
time (min) 
Outcome 
after revision 
 
1 78.2 M 0.01 52 OA  Dislocation MoM 60 
Died after 3.2 
yr  
 
2 32.7 F 0.02 50 DDH Dislocation MoM 67 
4.9 yr no 
complications 
 
 
 
 
3 56.2 F 0.69 52 OA 
Recurrent 
dislocation MoP 40 
0.1 yr re-
revised for 
dislocation 
(liner 
exchange) 
 
 
4* 49.1 F 1.00 54 OA 
Aseptic 
loosening 
femur OxP 185 
4.3 yr no 
complications 
 
 
 
 
 
 
 
5 59.9 F 1.05 52 OA 
Stem 
subsidence 
with LLD MoM 109 
0.1 yr re-
revised for 
periprosthetic 
stem fracture. 
Subsequent 
evacuation 
haematoma 2 
weeks later 
 
 
6 
58.6 F 1.25 54 OA 
Aseptic 
loosening 
cup MoM 60 
0.2 yr re-
revision for 
aseptic cup 
loosening 
 
7* 67.4 M 1.37 56 OA 
Deep 
infection 1st stage 103 
4.0 yr no 
complications 
 
8 78.7 M 1.69 54 OA ARMD MoP 80 
2.1 yr no 
complications 
 
 
66.9 M 1.81 60 OA Aseptic 
loosening 
MoP 305 2.2 yr stem 
lucency but    
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9* femur not re-revised 
 
 
 
 
10 71.3 F 1.86 52 OA LLD MoM 97 
 4.1 yr re-
revised for 
aseptic 
femoral 
loosening  
 
11* 70.6 F 1.96 52 OA 
Deep 
infection MoP 124 
3.6 yr no 
complications 
 
12 46.4 F 1.97 50 OA 
Unexplained 
pain CoP 60 
1.0 yr no 
complications 
 
13* 48.3 F 2.00 52 AVN 
Deep 
infection  MoM 90 
6.8 yr no 
complications 
 
14* 63.6 F 2.03 52 OA 
Recurrent 
dislocation CoP 48 
3.3 yr no 
complications 
 
15 73.4 F 2.25 52 OA LLD MoP 65 
3.6 yr no 
complications 
 
16 59.5 F 2.29 50 SUFE ARMD CoP 81 
1.4 yr no 
complications 
 
 
17 63.2 F 2.97 52 OA 
Aseptic 
loosening 
femur MoP 106 
2.3 yr no 
complications 
 
18* 
63.1 F 3.53 50 OA 
Peri-
prosthetic 
stem fracture MoP 128 
1.1 yr no 
complications 
 
19 70.3 F 3.66 52 OA ARMD CoP 60 
1.8 yr no 
complications 
 
20* 68.3 M 3.66 58 OA 
Deep 
infection 1st stage 114 
3.1 yr no 
complications 
 
21 58.1 F 3.69 50 OA ARMD CoP 66 
1.5 yr no 
complications 
 
22* 68.2 F 4.01 52 DDH 
Deep 
infection 1st stage 81 
1.4 yr no 
complications 
 
 
23 69.6 M 4.06 54 OA 
Aseptic 
loosening 
femur MoP 259 
0.9 yr no 
complications 
 
 
24* 60.7 F 4.08 52 OA 
Aseptic 
loosening 
femur MoP 117 
4.1 yr no 
complications 
 
25 67.8 F 4.20 52 OA ARMD CoP 81 
1.3 yr no 
complications 
 
 
73.0 F 4.22 52 OA ARMD MoP 183 1.0 yr lucency 
around 
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26 
acetabular 
component but 
not revised 
 
27 60.9 F 4.24 52 OA ARMD CoP 92 
0.9 yr no 
complications 
 
28* 61.6 F 4.43 52 OA ARMD CoP 90 
0.6 yr no 
complications 
 
29* 62.7 M 4.51 58 OA ARMD CoP 103 
0.7 yr no 
complications 
 
 
30* 72.7 F 4.83 52 OA 
Aseptic 
loosening 
cup MoP 106 
0.5 yr no 
complications 
 
31 70.5 M 5.01 54 AVN ARMD CoP 62 
0.3 yr no 
complications 
 
32* 72.3 F 5.23 54 OA ARMD OxP 118 
1.4 yr no 
complications 
 
 
33 
 
65.1 F 5.32 52 OA 
Aseptic 
loosening 
femur MoP 127 
1.5 yr no 
complications 
 
34* 69.5 F 5.84 52 OA ARMD CoP 46 
0.5 yr no 
complications 
35* 
69.8 F 6.06 52 OA ARMD CoP 65 
0.2 yr no 
complications 
 
36* 63.7 F 6.28 54 OA ARMD CoP 85 
0.1 yr no 
complications 
 
37* 67.2 F 7.33 52 OA ARMD CoP 110 
0.2 yr no 
complications 
 
38* 46.3 M 8.13 56 OA ARMD MoP 206 
0.1 yr no 
complications 
 
39 78.7 F 8.26 52 OA ARMD CoP 75 
0.1 yr no 
complications 
 
ARMD = adverse reaction to metal debris; AVN = avascular necrosis; CoP = ceramic-
on-polyethylene; DDH = developmental dysplasia of the hip; F = female; LLD = leg 
length discrepancy; M = male; MoM = metal-on-metal; MoP = metal-on-polyethylene; 
OA = osteoarthritis; OxP = oxinium-on-polyethylene; SUFE = slipped upper femoral 
epiphysis 
*Bilateral metal-on-metal hip bearing (total hip replacement or hip resurfacing). 
Revision 7 and 20 were in the same patient requiring bilateral revision arthroplasty.  
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All first-stage revisions performed for deep infection underwent successful second-stage 
revision total hip arthroplasty using a metal-on-polyethylene bearing.  
 
The cumulative survival for all THRs (n=578) was 94.1% (95% CI 91.3%-96.3%) at 5-
years (257 hips at risk) and 88.9% (95% CI 78.5%-93.4%) at 8-years (31 hips at risk) 
(Figure 3.2). Cumulative survival for male patients (n=238) was 96.3% (95% CI 92.4%-
99.1%) at 5-years (84 hips at risk) and 95.2% (95% CI 84.2%-98.7%) at 8-years (14 
hips at risk) with nine hips requiring revision. Cumulative survival for female patients 
(n=340) was 92.7% (95% CI 89.0%-95.7%) at 5-years (173 hips at risk) and 85.3% 
(95% CI 70.2%-92.1%) at 8-years (17 hips at risk) with 30 hips requiring revision. 
Gender did not significantly affect implant survival (p=0.053). 
 
Figure 3.2 Kaplan-Meier survival curve for all total hip replacements (n=578) 
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Revision for any indication was used as the endpoint for survival, with 39 hips revised 
in total. The shaded area represents the upper and lower limits of the 95% confidence 
intervals. The diagonal line represents the National Institute for Health and Clinical 
Excellence recommendations for implant survival (acceptable implant failure rate of up 
to 1% per year).  
 
ARMD was the commonest indication for revision surgery accounting for 44% (17 of 
39) of all revisions performed (Table 3.3). The mean acetabular inclination prior to 
ARMD revision for the 17 cases was 45.0° (range 37.5°-55.5°). The five hips (29%) 
with intraoperative evidence of macroscopic bearing wear all had acetabular 
components with excessive anteversion. Taper wear was observed macroscopically in 
six cases (35%) with four undergoing femoral component revisions and the other two 
less severe cases retaining their well-fixed femoral stems. There were no documented 
cases of wear or corrosion at the interface between the acetabular liner and acetabular 
component. All cases of ARMD were revised to a non-MoM articulation with no 
complications recorded at a mean of 0.8 years (range 0.1-2.1 years) following revision 
surgery (Table 3.2). Blood metal ions normalised following revision in all but the five 
most recently performed ARMD revisions. The mean acetabular inclination following 
ARMD revision was 45.7° (range 40.4°-51.6°). At the time of writing, none of the 
surviving 539 MoM THRs were awaiting revision surgery. 
 
Table 3.3 Details of 17 patients undergoing revision for adverse reaction to metal debris 
Revision  Initial    
cup  
inclination 
(degrees) 
Pre-revision 
blood metal 
ion levels 
(µg/l) 
Imaging Revision 
performed 
ARMD intra-
operative 
findings 
Histo-
pathology 
 
 
49.0 
Not 
USS + CT 
large joint Head, cup 
Milky effusion;  
granulomatous 
ARMD 
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8 performed effusion and liner infiltration;  cup 
over anteverted 
 
 
 
 
16 55.5 
Co 64.4  
Cr 36.3  
USS 
normal 
Head, cup 
and liner 
 
Metallosis; cup 
with excessive 
inclination and 
anteversion 
ARMD with 
prominent 
peri-vascular 
lymphocytic 
infiltrate 
 
 
 
 
 
 
19 39.7 
Not 
performed 
USS small 
effusion 
X-ray 
proximal 
femoral 
osteolysis 
Head and 
liner 
 
 
Milky effusion; 
granulomatous 
infiltration; cup 
over anteverted 
ALVAL 
 
 
 
21 39.9 
Co 9.7 
Cr 6.7  
USS 
effusion 
 
Head and 
liner 
Necrotic tissue 
in trochanteric 
bursa; free light 
brown watery 
fluid 
ALVAL 
 
 
 
 
 
25 42.4 
Co 1.8 
Cr 1.3 
USS 
effusion 
 
Head and 
liner 
Thickened 
trochanteric 
bursa with fluid 
content; 
thickened 
capsule with 
watery effusion 
ARMD with 
lymphocytic 
infiltrate 
 
 
 
 
 
 
 
 
26 
40.1 
Co 8.6  
Cr 2.8  
X-ray 
acetabular 
osteolysis 
with 
medial 
migration 
of socket 
MRI two 
large 
effusions 
 
Stemmed 
acetabular 
component 
and long 
femoral 
stem 
 
 
Abductor 
detachment; 
pelvic 
discontinuity; 
significant 
osteolysis of 
femur 
 
ARMD 
 
 
 
 
27 49.6 
Co 5.5  
Cr 1.0 
USS 
effusion 
Head, cup 
and liner 
15ml black 
stained fluid; 
metallosis; cup 
open and in 30 
degrees of 
anteversion 
ARMD 
 
 
28* 37.5 
Co 26.1 
Cr 16.3  
USS + 
MRI small 
effusion 
Head and 
liner 
Metallosis of 
abductors and 
trochanteric 
bursa 
ARMD 
 
 
 
 
 
 
 
 
45.5 
Co 0.7 
Cr 1.4 
USS 
effusion 
Stem, head 
and liner 
Extensive 
inflammatory 
haemorrhagic 
tissues; 
proximal 
femoral 
osteolysis 
exposing upper 
ARMD 
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29* 
3/4 of stem; 
osteolysis 
around cup 
 
 
 
 
31 45.7 
Co 3.8  
Cr 0.6  
CT and 
MRI 
moderate 
effusion 
Head and 
liner 
100 ml thick 
white fluid / 
metal debris; 
hip dislocating 
easily; anterior 
scar tissue 
ARMD 
 
 
32* 44.5 
Co 1.8  
Cr 1.2  
USS 
normal 
Stem, 
head, cup, 
and liner 
Metallosis; 
neutral cup; 
well fixed but 
proud stem 
ARMD 
 
 
 
34* 
38.5 
Co 10.2  
Cr 1.3  
MRI 
effusions 
Head and 
liner 
Mild effusion; 
necrotic tissue 
within capsule 
taper corrosion 
ARMD 
 
 
 
35* 43.2 
Co 8.9  
Cr 2.3  
USS + 
MRI small 
effusion 
 
Head and 
liner 
20 ml black 
stained metal 
debris fluid; 
taper stained 
black 
 
ARMD 
 
 
 
 
 
36* 46.3 
Co 8.7 
Cr 9.6  
USS + 
MRI 
moderate 
effusion 
 
Head and 
liner 
Breakdown of 
previous repair 
with black/grey 
fluid 
communicating 
with joint; 
metallosis 
 
 
ARMD 
 
 
37* 46.6 
Co 15.5  
Cr 10.1  
USS 
normal 
Head and 
liner 
Metallosis; well 
fixed 
components 
ARMD 
 
 
38* 
51.7 
Co 62.5  
Cr 37.2 
X-ray –
femoral 
osteolysis 
USS large 
effusion 
Long 
modular 
femoral 
stem and 
cup 
Large 
green/brown 
fluid collection; 
extensive 
metallosis; cup 
open and 
anteverted 
 
ARMD 
 
 
39 49.3 
Co 13.7  
Cr 8.1  
MRI 
normal 
Head and 
liner 
 
 
Metallosis 
 
ARMD 
 
Revision numbers correspond to those in Table 3.2 
ARMD = adverse reaction to metal debris; ALVAL = aseptic lymphocytic vasculitis 
associated lesion; Cr = chromium; Co = cobalt; CT = computerised tomography; MRI = 
magnetic resonance imaging; USS = ultrasonography scan 
*Bilateral metal-on-metal hip bearing (total hip replacement or hip resurfacing) 
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3.4.2 Blood metal ion analysis 
The median maximum blood metal ion concentrations recorded were 2.06 µg/l (IQR 
0.83-3.71 µg/l) for cobalt and 1.25 µg/l (IQR 0.83-2.03 µg/l) for chromium. Excluding 
revisions (n=39), 36 patients with 47 MoM THRs (8.7% of the non-revised cohort) had 
blood metal ion concentrations above 7 µg/l (Figures 3.3 and 3.4). Fifteen hips had 
raised blood cobalt and chromium concentrations and 32 hips had raised blood cobalt 
concentrations with normal chromium levels. 
 
Figure 3.3 Maximum whole blood cobalt concentration following metal-on-metal total 
hip replacement 
 
Dashed line = Medicines and Healthcare products Regulatory Agency safe level of 7 
µg/l; filled circles = hips which have been revised. 
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Figure 3.4 Maximum whole blood chromium concentration following metal-on-metal 
total hip replacement 
 
Dashed line = Medicines and Healthcare products Regulatory Agency safe level of 7 
µg/l; filled circles = hips which have been revised. 
 
Of the 25 unilateral MoM THRs with raised blood metal ion concentrations, 23 hips had 
normal hip ultrasonography and/or magnetic resonance imaging (under annual clinical 
follow-up) and two hips had periprosthetic fluid collections of variable sizes (under 
more regular review). Of the 11 patients (22 hips) with bilateral MoM THRs with raised 
blood metal ion concentrations, 17 hips had normal hip ultrasonography and/or 
magnetic resonance imaging (under annual clinical follow-up) and five hips had 
periprosthetic fluid collections of variable sizes (under more regular review). 
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3.4.3 Functional outcomes and radiological analysis 
Pre-operative and post-operative OHS data are summarised in Table 3.4. There was no 
statistically significant difference in absolute post-operative OHSs between males and 
females (p = 0.608). 
 
Excluding cases with initial femoral stem subsidence there were no changes in femoral 
or acetabular component position in hips not undergoing revision (n=539). All femoral 
(n=19) and acetabular (n=3) radiolucent lines observed during follow-up were non-
progressive (Table 3.4). There were no cases of femoral or acetabular osteolysis.  
 
Table 3.4 Functional and radiological outcomes following the 539 non-revised metal-
on-metal total hip replacements 
Functional 
outcome 
Median pre-operative OHS (IQR) 
 
Overall 
 
 
Female 
 
 
Male 
 
Median post-operative OHS (IQR) 
 
Overall 
 
 
Female 
 
 
Male 
 
 
 
66.7% (54.2%-79.2%) 
16/48 (10-22) 
 
70.8% (58.3%-81.3%) 
14/48 (9-20) 
 
62.5% (50.0%-72.9%) 
18/48 (13-24) 
 
 
6.3% (0%-27.1%) 
45/48 (35-48) 
 
6.8% (0%-27.1%) 
44.7/48 (35-48) 
 
6.3% (0%-25.5%) 
45/48 (36-48) 
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Radiological 
outcome 
Mean acetabular component inclination 
(range) 
 
Mean femoral stem subsidence  
(range) 
 
Femoral radiolucent lines (zones 1 and 7) 
 
 
Acetabular radiolucent lines (zone 1) 
44.0o   
(21.1o-58.3o) 
 
1 mm  
(0-7 mm) 
 
19 hips (3.5% of non-
revised hips) 
 
3 hips (0.6% of non-
revised hips) 
 
 
IQR = interquartile range; OHS = Oxford Hip Score (provided as a percentage and on a 
scale of 0-48) 
 
3.5 Discussion 
This represents one of the largest single centre studies reporting medium-term outcomes 
on any modern MoM THR system [37,38,89]. Furthermore, we are unaware of any 
independent reports on outcomes for this particular THR system.  
 
The present findings demonstrated lower than expected implant survival at eight-years 
(88.9%). Although survival was not significantly different between genders it was 
below that expected in published guidelines from NICE [80]. The survival curve 
appears to diverge from these guidelines at the four-year point (Figure 3.2), which is 
most likely due to 13 of 17 ARMD revisions occurring after this time. However good 
functional outcomes were reported in non-revised patients, which are comparable to 
those reported in young patients following HR [50-54,90]. ARMD was the commonest 
cause of failure requiring revision with this THR system. In light of recent findings 
from registry data confirming stemmed MoM hip replacements have significantly 
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higher revision rates than non-MoM articulations [55,91], it is advised that MoM THRs 
should not be implanted in the future with regular surveillance recommended for 
patients with these bearings in-situ.  
 
Although ARMD was the commonest indication for revision, it only accounted for 44% 
of all revisions performed. More traditional modes of THR failure (such as aseptic 
loosening, dislocation, and deep infection) were responsible for the remaining revisions 
performed. In contrast, previous studies reporting on MoM THRs observed that ARMD 
accounted for nearly all the revisions performed (at least 82%) [37,38]. One potential 
explanation for this relates to differences in implant metallurgy, with studies 
demonstrating that subtle differences in HR design can have a significant impact on 
failure rates [36,41].  
 
Another reason may relate to femoral head size. Recent observations suggest that larger 
femoral head sizes are associated with increasing failure rates in MoM THRs [55,92]. 
Potential explanations for these findings include higher wear at the taper-head interface 
due to increased mechanical stress on the taper with larger heads [37,38], failure to 
achieve optimum lubrication, and/or early loosening due to increased transmitted torque 
when using larger femoral heads [55]. The femoral head sizes implanted in this cohort 
(median 36 mm) were smaller than those used in previous studies reporting higher 
failure rates (range 38-58 mm) [37,38]. No 28 mm femoral heads used in the present 
series have required revision.  
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The lower failure rates for ARMD observed in this study compared to previous reports 
[37,38] may also be related to cases being performed by surgeons experienced in HR 
[50,69,90]. The mean acetabular component inclination in this series was acceptable at 
44.0o with 10 of 17 ARMD revisions also having acceptable acetabular component 
inclination.  
 
It is important MoM THR patients undergo regular clinical surveillance as they may 
eventually develop ARMD. In this cohort, 8.7% of non-revised hips had blood metal 
ion concentrations above MHRA thresholds. The subgroups in which management 
remains unclear are patients with: (1) high blood metal ion levels and normal imaging 
findings (n=40), and (2) raised metal ion levels (most with bilateral MoM bearings) and 
periprosthetic fluid collections of variable sizes (n=7). Repeat blood metal ion sampling 
and cross-sectional imaging may assist in identifying ARMD [13,48], however the 
natural history of ARMD is not well understood [93,94]. Decisions relating to revision 
surgery must therefore be considered on a case-by-case basis. This should include 
thorough discussion with the patient about the potential risks of further surveillance as 
well as the risks associated with revision surgery [46]. More detailed investigative and 
treatment algorithms should be developed for patients with suspected ARMD as new 
evidence becomes available regarding its natural history.   
 
In addition to the common findings of metallosis and acetabular component 
malposition, a variety of other intra-operative findings were observed in the 17 ARMD 
revisions performed. These included effusions of variable sizes and consistencies, 
51	  
	  
granulomas, tissue necrosis, and osteolysis. This heterogeneity of findings in hips 
revised for ARMD was also observed in an earlier report from this centre on HRs [95] 
as well as by other authors [35,96], and is likely to be related to the complex and 
incompletely understood pathogenesis of this condition.  
 
The macroscopic implant analysis and opinions of the surgeons revising the MoM 
THRs in this study were that failure for ARMD with this particular device was due to 
wear at the stem taper and femoral head interface, combined with excessive wear from 
the bearing surface (femoral head and acetabular liner interface) in cases of acetabular 
component malpositioning. Taper junction failure requiring revision for large-diameter 
MoM THRs has certainly been implicated previously as the main failure mechanism for 
these implants [37,38]. There is evidence that significant volumetric material loss 
occurs at the taper junction which exceeds that taking place at the bearing surface [92]. 
Furthermore, a recent retrieval analysis of 20 failed 36mm MoM THRs demonstrated 
significantly greater femoral head taper material loss from Corail stems compared to S-
ROM stems [97]. The rougher and shorter Corail stem taper design was considered 
responsible for this finding [97]. However, other recent reports have identified the 
interface between the acetabular liner and acetabular component as a source of 
significant metal wear and corrosion for a number of large-diameter MoM THR 
designs, including the Pinnacle cup [98,99]. Therefore it is suspected the failure 
mechanism of modern large-diameter MoM THRs is multifactorial and requires more 
detailed investigation. 
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All revisions for ARMD in the present series underwent bearing exchange to non-MoM 
articulations with subsequent normal blood metal ion concentrations and no 
complications reported at short-term follow-up. Nevertheless, given the poor outcomes 
reported following revision arthroplasty for ARMD [46] these patients will continue to 
have regular follow-up.  
 
This study has some recognised limitations. The follow-up period may be considered 
relatively short. However this THR system was only implanted from 2004, therefore it 
is not possible to determine long-term outcomes at this stage. Other studies reporting on 
these devices have similar follow-up periods [37,38]. In addition, although all patients 
were reviewed after the institutions recall 8% have a follow-up of less than three years. 
This reflects the logistical challenge of reviewing large numbers of patients in clinic 
with over 4000 MoM hips implanted at this centre. Understandably it has taken time to 
achieve complete follow-up after the recall, therefore some patients are yet to reach 
their second clinical review. It was not possible to accurately measure anteversion of the 
acetabular component from pelvic radiographs. This study also spans a time when 
subtle nuances of anteversion and combined anteversion were not fully appreciated [81] 
and which may have been responsible for some ARMD failures. Although it was not 
routine practice during the study, some surgeons did send a selection of implants for 
forensic explant analysis (maximum of ten). These reports would provide more detail 
regarding the mechanisms of implant failure. However they were not easily available 
for further analysis given some forensic reports were obtained for medico-legal reasons, 
whilst others were analysed externally and therefore annonymised for confidentiality.  
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In conclusion, the medium-term results of this MoM THR system demonstrated good 
functional outcomes in non-revised patients with less dramatic failure rates compared to 
similar devices [37,38]. However survival was still below that recommended in 
published guidelines from NICE [80]. On the basis of the available evidence it is 
recommended large-diameter MoM THRs are not implanted in the future. Patients who 
currently have these implants should have regular clinical surveillance so that ARMD 
can be identified and treated early.   
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CHAPTER 4 
A SYSTEMATIC REVIEW OF OUTCOMES FOLLOWING REVISION          
OF METAL-ON-METAL HIP RESURFACINGS AND TOTAL HIP 
REPLACEMENTS FOR ADVERSE REACTION TO METAL DEBRIS 
 
4.1 Declaration 
The work detailed in this chapter has been published in a peer reviewed journal. As first 
author of this work my role involved designing the systematic review, and providing 
significant input in performing the review, data collection, statistical analysis, data 
interpretation, and the writing of all versions of the paper submitted to the journal as 
well as this chapter.  
 
Matharu GS, Pynsent PB, Dunlop DJ. Revision of metal-on-metal hip replacements and 
resurfacings for adverse reaction to metal debris: a systematic review of outcomes. Hip 
International 2014; 24(4): 311-320.    
 
4.2 Introduction 
In recent years ARMD has become a recognised mode of failure of MoM HRs and 
THRs with this condition often requiring revision arthroplasty (Chapter 1.2). Between 
2003 and 2012, 67,363 MoM hips (35,470 HRs and 31,893 THRs) were implanted in 
England, Wales, and Northern Ireland [2]. Failure rates at 9-years have been reported as 
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12.3% for all HRs and up to 21.4% for stemmed MoM THRs [2]. Overall ARMD has 
accounted for 7.4% of all revision hip replacements performed in England, Wales, and 
Northern Ireland, however this is increasing with ARMD responsible for 13.2% of all 
hip revisions performed in 2012 [2]. 
 
As ARMD is a relatively new mode of hip failure little is currently known about the 
outcomes following revision arthroplasty. Both the MHRA [48] and orthopaedic experts 
[13] recommend early surgical intervention for ARMD based on a small study of 16 
HRs revised for pseudotumour which experienced high short-term complication (50%) 
and re-revision (38%) rates [46]. These unsatisfactory outcomes are concerning given 
most patients are young and active [25-32]. Importantly this study did not report on 
patients with MoM THRs which can have additional problems related to taper wear 
[37,38]. Given the large number of MoM hips implanted worldwide it is important 
surgeons are aware of the likely outcomes following ARMD revision surgery so 
patients can be appropriately counselled pre-operatively regarding the risks of revision.  
 
The aim of this systematic review was to assess the clinical outcomes following revision 
of MoM HRs and THRs for ARMD.    
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4.3 Methods  
 
4.3.1 Search strategy 
A systematic literature review was conducted to assess the evidence on clinical 
outcomes following revision of MoM HRs and THRs for ARMD. The search was 
performed independently by two reviewers (GSM and PBP) using PubMed, Medline, 
Embase, and the Cochrane Central Register of Controlled Trials to identify relevant 
articles published between 1st January 2009 and 1st July 2013. The search started from 
2009 as this was when the first study reporting outcomes following ARMD revision was 
published [46]. 
 
Combinations of the following search terms were used in each electronic database: 
‘adverse reaction to metal debris (ARMD)’, ‘adverse local tissue reaction (ALTR)’, 
‘aseptic lymphocytic vasculitis associated lesions (ALVAL)’, ‘pseudotumour’, 
‘pseudotumor’, ‘metal-on-metal’, ‘hip resurfacing’, ‘total hip replacement’, ‘total hip 
arthroplasty’, ‘failure’, ‘revision surgery’, ‘outcomes’, ‘clinical outcomes’, and 
‘functional outcomes’. There was no restriction on language, study type, or publication 
status. Full text articles were obtained of all potentially relevant studies and assessed 
independently by both reviewers. Additional review was performed of pertinent 
references from the bibliographies of these publications not found in the electronic 
search but fitting the inclusion criteria. 
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4.3.2 Study inclusion and exclusion criteria 
Studies were included if they specifically reported on clinical outcomes following 
revision of MoM HRs and/or THRs for ARMD. Only studies reporting cohorts with 
more than ten MoM HRs and/or more than ten MoM THRs undergoing revision for 
ARMD were included. This was to eliminate small case series which may be influenced 
by learning curves, and to minimise any selection and publication bias of “positive” 
results. No restrictions were placed on the minimum follow-up period of patients 
following revision in the studies identified. Any duplicate publications identified were 
excluded. If multiple publications from centres reporting on the same cohort were 
found, only the most recent article was included.    
 
4.3.3 Quality of included studies  
The methodological quality of each study was independently assessed by two reviewers 
using the Oxford Centre for evidence-based medicine levels of evidence [100]. Any 
disagreement was resolved by discussion and consensus with the third author (DJD).   
 
4.3.4 Data collection and outcomes of interest  
Studies were categorised into those reporting on clinical outcomes of MoM HRs 
following revision arthroplasty for ARMD and those reporting on MoM THRs revised 
for ARMD. All study data were independently extracted and recorded in relevant data 
tables by two reviewers. Data extracted included: patient demographics (age and 
gender), implants requiring revision, time from index arthroplasty to revision, follow-up 
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time, and clinical outcomes (complications, further surgery including re-revision, and 
functional outcomes) after ARMD revision. 
 
Defined outcomes of interest following ARMD revision surgery were: (1) complication 
rates, (2) re-revision rates, including re-revisions performed for recurrent ARMD or 
pseudotumour, (3) surgical intervention other than re-revision, (4) functional outcomes. 
If studies reported functional outcomes following revision arthroplasty, the specific 
instrument and scoring method used was extracted from the original report and recorded 
to assist comparison between studies. Meta-analysis of the pooled data was not 
performed due to the heterogeneity between studies in terms of implants used and data 
reported.  
 
4.4 Results 
 
4.4.1 Studies for review  
The systematic review identified 393 articles with six studies [46,58,101-104] meeting 
the inclusion criteria for analysis (Figure 4.1). Of the six studies reviewed, one was a 
retrospective case-control study [46] and the remaining five were either prospective or 
retrospective case-series’ [58,101-104]. All six studies were graded as level 4 evidence 
[100]. Two studies [58,101] reported on clinical outcomes following ARMD revision of 
both MoM HRs and THRs. Although both studies reported outcomes of more than ten 
HR revisions which were included in this review, they also reported the outcomes of 
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either two [101] or seven [58] THR revisions for ARMD which were excluded from 
further analysis.  
 
Figure 4.1 PRISMA flow diagram showing article selection for the systematic review 
 
ARMD = adverse reaction to metal debris 
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4.4.2 Patient demographics 
Relevant patient demographic data from the six studies is summarised in Table 4.1. 
From the six studies a total of 216 MoM hip bearings were revised for ARMD (197 
HRs and 19 THRs) with clinical outcome data. Mean age at revision in the six studies 
ranged from 49.8 years to 57.7 years with between 36% and 100% of patients being 
female. Mean time from primary arthroplasty to ARMD revision ranged from 19.0 
months to 51.4 months.    
 
Table 4.1 Demographics of patients revised for adverse reaction to metal debris from 
the six studies 
Study and year 
of publication 
Mean age 
(range) at 
revision 
in years 
Female 
hips 
(%) 
Hips 
revised 
for 
ARMD 
(patients) 
Prostheses 
revised 
Mean 
time to 
ARMD 
revision 
(range) in 
months 
Grammatopoulos 
2009 [46] 
51.3    
(20-71) 
 16/16 
(100) 
16 (16) 
HR  
Included 
BHR, 
Cormet, 
Conserve 
Plus, and Re 
Cap (exact 
numbers NS) 
19.0   
(0.1-80)* 
  
Rajpura 
2011 [101] 
53.5    
(22-67) 
4/11 
(36) 
11 (11) 
HR 
8 BHR,           
2 Cormet,        
1 ASR 
46.0    
(15-87)  
De Smet 
2011 [102] 
52.5    
(18-71)* 
69  
(61)* 
48 (45) 
HR 
Included 
BHR, 
McMinn, 
Conserve 
Plus, ASR, 
Durom, 
Adept, 
32.5      
(4-101)  
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Cormet, and 
Re Cap* 
Liddle      
2013 [58] 
57.7    
(25-74) 
26/32 
(81) 
32 (29) 
HR 
20 BHR, 5 
Cormet, 4 
ASR, 2 
Biomet, 1 
Mitch    
51.4     
(11-131) 
Pritchett 
2013 [104]  
49.8    
(32-71) 
43/90 
(48) 
90 (89) 
HR 
35 BHR, 32 
Conserve 
Plus, 8 ASR, 
7 Cormet, 4 
Re Cap, 4 
Durom 
33.3    
(16-59) 
Munro 
2013 [103] 
57.5    
(46-76)* 
NS 
(37)* 
19 (NS) 
THR* 
19 Durom  34.0      
(7-59)* 
 
ARMD = adverse reaction to metal debris; ASR = Articular Surface Replacement; BHR 
= Birmingham Hip Resurfacing; HR = hip resurfacing; NS = not stated; THR = total hip 
replacement 
*Studies did not provide the relevant data specifically for the cohort of patients 
undergoing revision for adverse reaction to metal debris (but rather for the whole cohort 
of revisions they reported on).  
 
4.4.3 Outcomes following ARMD revision surgery  
All six studies reported data on complications, re-revision surgery, and functional 
outcomes (Table 4.2 and 4.3). Only one study specifically reported on performing 
further surgery other than re-revision during follow-up [103]. In one study 
complications and re-revisions were reported for the whole cohort rather than just for 
ARMD revisions [102]. In another study [58] it was not possible to determine whether 
the complications and re-revisions occurred in the 32 HRs included in this review, or 
the seven MoM THRs excluded from further analysis. Therefore complication and re-
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revision rates for both studies [58,102] have been provided as ranges rather than 
absolute values. 
Table 4.2 Clinical outcomes reported in five studies following revision of metal-on-
metal hip resurfacings for adverse reaction to metal debris 
 Grammatopoulos 
2009 [46]  
Rajpura 
2011 [101] 
De Smet 
2011 [102] 
Liddle 
2013 [58] 
Pritchett 
2013 [104] 
Revision 
bearing used 
(%) 
CoC 8/16 (50) 
CoP 6/16 (38) 
MoP 2/16 (12)  
CoC      
9/11 (82)  
MoP      
1/11 (9) 
Pseudo-
arthrosis  
1/11 (9)  
CoC (67)* 
MoM (33) 
CoC     
24/32 (75) 
MoP      
6/32 (19) 
MoM     
2/32 (6) 
MoP  
47/90 (52) 
MoM 
43/90 (48) 
Mean (range) 
follow-up 
time from 
revision in 
months 
36                      
(10-86)* 
21         
(12-40) 
43           
(3-121)* 
Median 30 
(12-54)* 
61        
(36-118) 
Total 
complications 
(%) 
8/16 (50) 
 
Dislocation (n=3) 
Nerve palsy (n=3) 
Aseptic cup 
loosening (n=2) 
2/11 (18) 
 
ARMD 
recurrence 
(n=2) 
<11/48 
(<23)* 
 
Dislocation 
(n=5) 
Deep 
infection 
(n=3) 
Component 
loosening 
(n=2) 
Metal 
sensitivity 
(n=1) 
<2/32 (<6)* 
 
Dislocation 
(n=1) 
Recurrent 
pseudo-
tumour / 
aseptic cup 
loosening 
(n=1) 
 
4/90 (4) 
 
ARMD 
recurrence 
(n=1) 
Deep 
infection 
(n=1) 
Aseptic 
cup 
loosening 
(n=1) 
Acetabular 
fracture 
(n=1) 
Hips 
requiring re-
6/16 (38)  2/11 (18)  
ARMD 
<6/48   
(<13)* 
<2/32 (<6)* 
Dislocation 
3/90 (3) 
ARMD 
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revision (%) Dislocation (n=3) 
Aseptic cup 
loosening (n=2) 
NS  (n=1)  
3 of these re-
revised hips also 
had evidence of 
recurrent 
pseudotumour 
recurrence 
(n=2) 
Component 
loosening 
(n=2) 
Deep 
infection 
(n=2) 
Dislocation 
(n=1) 
Metal 
sensitivity 
(n=1) 
(n=1) 
Recurrent 
pseudo-
tumour / 
aseptic cup 
loosening 
(n=1) 
 
 
recurrence 
(n=1) 
Deep 
infection 
(n=1) 
Aseptic 
cup 
loosening 
(n=1) 
 
Surgery other 
than re-
revision (%) 
0/16 (0) 0/11 (0) 0/48  (0) 0/32 (0) 0/90 (0) 
Functional 
outcome 
scores 
following 
revision 
Mean OHS            
= 20.9 (/48) 
48 = best outcome 
Mean OHS 
= 35.3 (/48) 
48 = best 
outcome 
Mean HHS 
= 93.1* 
(/100) 
100 = best 
outcome 
Median 
OHS           
= 36.5 (/48) 
48 = best 
outcome 
Mean HHS 
= 93.2 
(/100) 
100 = best 
outcome 
Additional 
study findings 
and 
comments 
Significantly worse 
clinical and 
functional 
outcomes compared 
to: 
(1) HRs revised for 
other indications  
and 
(2) Patients 
undergoing primary 
total hip 
replacement 
Pseudo-
arthrosis 
patient had 
satisfactory 
function so 
no re-
revision 
planned  
3 of 11 
patients had 
no OHS 
before 
and/or after 
revision 
Presence of 
soft-tissue 
fluid 
collection 
did not 
affect 
outcome 
after 
revision 
Patients 
with solid 
pseudo-
tumours 
and those 
revised to 
MoM 
bearings 
had worse 
functional 
outcomes   
All hips 
had only 
one HR 
component 
revised for 
ARMD 
All re-
revisions 
were in 
those 
retaining a 
MoM hip 
bearing 
 
ARMD = adverse reaction to metal debris; CoC = ceramic-on-ceramic; CoP = ceramic-
on-polyethylene; HHS = Harris Hip Score; HR = hip resurfacing; MoM = metal-on-
metal; MoP = metal-on-polyethylene; OHS = Oxford Hip Score; NS = not stated  
*Studies did not provide the relevant data specifically for the cohort of patients 
undergoing revision for adverse reaction to metal debris (but rather for the whole cohort 
of revisions they reported on). 
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Table 4.3 Clinical outcomes reported in one study following revision of metal-on-metal 
total hip replacements for adverse reaction to metal debris 
 Munro 2013 [103] 
Revision bearing used* Metal-on-polyethylene 75% 
Ceramic-on-polyethylene 25% 
Mean (range) follow-up time 
from revision in months* 
25 (10-48) 
Total complications (%) 13/19 (68) 
Dislocation (n=5) 
ARMD recurrence (n=3) 
Aseptic cup loosening (n=3) 
Nerve injury (n=2) 
Hips requiring re-revision (%) 4/19 (21) 
Dislocation and / or aseptic cup loosening (n=3) 
ARMD recurrence (n=1) 
Surgery other than re-revision 
(%) 
5/19 (26)  
Dislocations reduced under anaesthesia  
Functional outcome scores  
following revision* 
Mean WOMAC (pain) 78 (/100) 
Mean WOMAC (function) 83 (/100) 
0 = best outcome 
Additional study  
findings and comments 
High failure rate of ‘fiber’ metal cups 
High dislocation rate despite using large heads 
 
ARMD = adverse reaction to metal debris; WOMAC = Western Ontario and McMaster 
Universities Arthritis Index 
*Study did not provide the relevant data specifically for the cohort of patients 
undergoing revision for adverse reaction to metal debris (but rather for the whole cohort 
of revisions they reported on). 
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4.4.4 Outcomes following HR revision for ARMD 
Five [46,58,101,102,104] of the six included studies reported outcomes following 
ARMD revision in HR patients (Table 4.2). Mean follow-up time from ARMD revision 
ranged from 21 months to 61 months. During this time the complication and re-revision 
rates reported were between 4% to 50% and 3% to 38% respectively. The commonest 
complications were dislocation (n=9 amongst the five studies), ARMD and/or 
pseudotumour recurrence (n=8), and aseptic acetabular component loosening (n=6). 
These three complications were also the commonest indications for re-revision surgery. 
All five studies reported between one and three cases of ARMD and/or pseudotumour 
recurrence during follow-up. ARMD and/or pseudotumour recurrence accounted for 
between 17% (1/6) and 100% (2/2) of all re-revisions performed. 
 
Functional outcomes following ARMD revision were reported in all studies using one 
of two different instruments. In one study three of eleven revised hips did not have pre-
operative and/or post-operative functional outcomes available [101]. Another study only 
reported post-operative functional outcomes therefore change in score could not be 
determined [46]. Functional outcomes following ARMD revision were good or 
satisfactory in all but one study [46].   
 
4.4.5 Outcomes following THR revision for ARMD  
One [103] study reported outcomes following ARMD revision in THR patients (Table 
4.3). At a mean follow-up time of 25 months from ARMD revision the complication 
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rate was 68% and the re-revision rate was 21%. The commonest complications were 
dislocation (n=5), ARMD recurrence (n=3), and aseptic acetabular component 
loosening (n=3). These were also the commonest indications for re-revision surgery. In 
addition to re-revision, 26% of patients required closed reductions for dislocated THRs. 
Post-operative functional outcomes following ARMD revision were reported, however 
no pre-revision scores were available to determine change in score. Functional 
outcomes following ARMD revision were generally poor.   
 
4.5 Discussion  
It is important for arthroplasty surgeons to have a good understanding of the clinical 
outcomes which can be expected in patients following revision of MoM hips for 
ARMD. With the revision burden for ARMD increasing, especially in specialist centres 
[58,102], it is vital patients receive appropriate pre-operative counselling regarding the 
likely outcomes following ARMD revision surgery. This is perhaps of even greater 
importance when counselling asymptomatic individuals with clinically well functioning 
prostheses in whom revision for ARMD is recommended based on other investigations. 
 
This systematic review has demonstrated that since an initial report in 2009 observing 
poor short-term outcomes following revision of HRs for pseudotumour [46], few studies 
have been published on outcomes following ARMD revision [58,101-104]. 
Furthermore, all studies reviewed were graded as low-quality evidence (level 4) with 
most limited by reporting on small cohorts with short-term follow-up [46,58,101,103]. 
It is recognised that given the potential ethical issues of not revising patients with 
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ARMD and the heterogeneity between patients with this diagnosis [58] it is unlikely 
better quality evidence, such as from randomised trials, will be obtained in the future.    
 
Outcomes following ARMD revision in the studies reviewed were variable. 
Complication rates ranged from 4% to 68% and re-revision rates between 3% and 38% 
[46,58,101-104]. These generally high complication rates are of concern given they are 
reported at largely short-term follow-up. In addition, for HR patients who often 
comprise a young and active group [25-32] these outcomes appear significantly inferior 
to those reported following HRs revised for other indications [105-107]. Interestingly 
one study reporting on 48 HRs revised for ARMD and 65 HRs revised for other 
indications demonstrated outcomes were not affected by the presence of a soft-tissue 
fluid collection [102]. However the authors acknowledge their outcomes following 
ARMD revision have improved with increasing experience [102]. 
 
Of further concern is the high complication (68%) and re-revision (21%) rates observed 
in the short-term in the only study reporting on MoM THRs revised for ARMD [103]. 
All but one hip revised retained their well-fixed femoral stem, therefore these 
complication rates do not even reflect the additional problems which can be associated 
with removing a stemmed femoral component [108,109]. In addition the morbidity 
following ARMD revision in some studies may have been underestimated 
[46,58,101,102,104] given only one study specifically reported on further surgery 
performed other than re-revision [103]. Not all dislocations and deep infections reported 
as a complication underwent re-revision. It is possible such patients underwent further 
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procedures, such as closed prosthetic reductions or wound washouts, which were not 
recorded but would add to overall morbidity.        
 
Three complications were common to most studies following ARMD revision, namely 
dislocation, ARMD and/or pseudotumour recurrence, and acetabular component 
loosening. Dislocation was the commonest complication with most cases requiring re-
revision. This complication is predisposed to by a combination of stretching and 
damage to the hip abductors and/or short external rotators caused by the adverse 
reaction itself, and the subsequent excision of periprosthetic tissues affected by ARMD 
which may include the hip capsule [102]. Two studies did not report any dislocations 
following ARMD revision [101,104], which may reflect these patients had less severe 
soft-tissue destruction at revision. Studies reporting on patients with more severe soft-
tissue destruction observed poorer outcomes [46,58]. Grammatopoulos et al. reported 
significantly worse clinical and functional outcomes in patients with HRs revised for 
pseudotumour than matched patients undergoing primary THR, and compared to HRs 
revised for other indications [46]. In another study the only two re-revisions performed 
occurred in the subgroup of four patients with solid pseudotumours [58]. This subgroup 
also experienced significantly inferior functional outcomes compared to other patients 
[58]. If the degree of soft-tissue destruction is time-dependent these findings would 
support early and aggressive surgical intervention for ARMD.  
 
All six studies reported at least one case of ARMD and/or pseudotumour recurrence 
during follow-up [46,58,101-104]. Incomplete initial resection and leaving substantial 
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amounts of metal wear debris may explain such recurrence [46,58]. In addition, 
incomplete initial debridement may increase the risk of secondary infection [58,103]. 
We recommend that excision of ARMD lesions is considered an oncological procedure 
with clear resection margins required to reduce the risk of recurrence [110]. However 
these intentions may become compromised when surgeons attempt to preserve soft-
tissue for hip joint stability. As these lesions may involve vital neurovascular structures 
and/or extend into the pelvis it is important to perform detailed pre-operative imaging 
and enlist the appropriate expertise when performing revision surgery, such as vascular 
surgeons and specialists in pelvic and soft-tissue reconstruction. The management 
algorithm proposed by Liddle et al. highlights the heterogeneity of findings encountered 
at revision in patients with MoM hips and provides a good basis for surgical planning 
[58].  
 
Recurrence of ARMD can also be caused by the bearing implanted at revision. Poorer 
clinical and/or functional outcomes were observed in ARMD patients revised using 
MoM articulations [58,104]. It is suspected the persistence of a MoM bearing provides a 
source of metal wear debris which can continue to cause periprosthetic tissue reactions. 
It is therefore recommended that non-MoM bearings are used for ARMD revisions with 
CoC and ceramic-on-polyethylene (CoP) articulations currently most popular 
[46,58,101-104]. In one study two of the three patients developing ARMD recurrence 
had initially been revised to MoP bearings [103]. It was postulated these recurrences 
were due to wear debris generated from the metal femoral head articulating with the 
metal stem taper and that in these instances the use of ceramic heads with titanium 
sleeves may be appropriate, though requires further research [103].  
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The best outcomes reported following ARMD revision were from a study performing 
90 one-component HR revisions (complication rate 4% and re-revision rate 3%) [104]. 
Although this study described an interesting and novel method of managing ARMD 
associated with HRs [104], this approach cannot be recommended without longer-term 
follow-up in light of current evidence. Registry data reports unacceptably high revision 
rates following acetabular component only HR revisions [111] with surgeons 
experienced in HR also reporting inferior outcomes following single component 
revisions [102]. After observing inferior outcomes in ARMD patients revised to MoM 
bearings Liddle et al. recommended revision of MoM hips for any reason should always 
include both sides of the bearing surface and result in a non-MoM articulation [58]. We 
agree with this recommendation in the current climate of uncertainty about the use of 
MoM hip bearings in any context apart from carefully selected patients undergoing HR 
[50-52,90]. Indeed all three re-revisions performed by Pritchett et al. were in patients 
retaining MoM bearings with one re-revision performed for ARMD recurrence [104].      
 
In conclusion, limited evidence is presently available regarding clinical outcomes 
following revision of MoM hips for ARMD, especially for large-diameter THRs. This 
must be addressed in future studies so surgeons can better inform their patients pre-
operatively about the risks of undergoing revision for ARMD. Such information will 
especially by important when counselling asymptomatic individuals in whom revision 
for ARMD is recommended, and may also be informative in protecting arthroplasty 
surgeons from a medico-legal perspective. 
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CHAPTER 5 
OUTCOMES FOLLOWING REVISION OF METAL-ON-METAL HIP 
RESURFACINGS AND TOTAL HIP REPLACEMENTS FOR                
ADVERSE REACTION TO METAL DEBRIS 
 
5.1 Declaration 
The work detailed in this chapter was accepted for publication in a peer reviewed 
journal on 22nd August 2014. As first author of this work my role involved input with 
study design, data collection including all radiographic analysis, involvement with 
statistical analysis and data interpretation, and the writing of all versions of the paper 
submitted to the journal as well as this chapter.  
 
Matharu GS, Pynsent PB, Sumathi VP, Mittal S, Buckley CD, Dunlop DJ, Revell PA, 
Revell MP. Predictors of time to revision and clinical outcomes following revision of 
metal-on-metal hip replacements for adverse reaction to metal debris. The Bone and 
Joint Journal 2014 (In Press).  
 
5.2 Introduction 
A number of patients with MoM HRs and THRs who develop ARMD eventually 
require revision surgery (Chapter 1.2). For these patients it is a pivotal time in their 
care. The surgeon has a number of decisions to make both pre-operatively, using results 
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from blood tests and radiological examinations to plan surgery, and intra-operatively, 
based on the findings at revision. These findings include bone loss and muscle damage, 
which can both vary from minimal to catastrophic, and periprosthetic effusions which 
range from negligible to large solid or semi-solid pseudotumours [35,36,95]. 
 
The few studies reporting outcomes following revision of MoM hips for ARMD suggest 
outcomes are generally poor with short-term complication and re-revisions rates up to 
68% and 38% respectively (Chapter 4). Because of the need for caution in a condition 
where there is tissue destruction and some uncertainty about the natural history, early 
surgical intervention is often recommended [13,46,48]. Knowledge of prognostic factors 
of outcome would be useful for surgeons in making decisions related to revision 
surgery. Only one study has specifically examined any factors affecting outcome 
following ARMD revision which observed poorer outcomes in patients with solid 
pseudotumours and those revised to stemmed MoM hips [58].  
 
In addition, it is possible the specific histopathological response in local tissues may 
affect outcomes following ARMD revision. Recent work demonstrated a subgroup of 
ARMD patients exhibited an immune reaction with local appearances of tertiary 
lymphoid organs (TLOs) [112]. These TLO structures have been observed in several 
autoimmune conditions [113], therefore it is possible patients with such structures have 
more aggressive disease.  
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The study aims were to determine the clinical outcomes following revision of MoM 
HRs and THRs for ARMD, and identify factors predictive of outcomes following 
ARMD revision. It was hypothesised poorer outcomes would be observed in (1) patients 
with TLO structures, and (2) patients retaining MoM bearings following ARMD 
revision, either as a contralateral MoM bearing or revision to another MoM articulation. 
The second hypothesis is particularly relevant at revision because it may influence the 
surgeon’s choice of bearing surface.  
 
5.3 Methods 
 
5.3.1 Study design and patient cohort 
This retrospective study was approved and registered with the relevant hospital 
department. Between January 1998 and March 2012, 64 MoM hips in 63 patients 
underwent revision for ARMD (Table 5.1). All revisions were performed at one 
specialist arthroplasty centre (The Royal Orthopaedic Hospital, Birmingham). 
Operations were performed in a clean-air laminar flow operating theatre by nine 
surgeons. Sixty-one operations were performed through a posterior surgical approach 
with the remaining three hips revised using an anterolateral approach.   
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Table 5.1 Summary of the study cohort 
Characteristic Whole cohort HR THR 
 
Number of hips (%) 64 (100) 46 (72) 18 (28) 
Female (%) / Male (%) 46 (72) /       
18 (28) 
34 (74) /       
12 (26) 
12 (67) /         
6 (33) 
Mean age at revision in 
years (range) 
57.8          
(31.0-78.8) 
55.8           
(31.0-71.2) 
63.2          
(48.3-78.8) 
Indication for metal-on-
metal HR or THR (%) 
OA 49 (77) 
DDH 5 (8) 
SUFE 5 (8) 
AVN 4 (6) 
NOF 1 (1) 
OA 34 (74) 
DDH 5 (11) 
AVN 4 (9) 
SUFE 3 (6) 
OA 15 (83) 
SUFE 2 (11) 
NOF 1 (6) 
Previous hip surgery prior to 
index arthroplasty (%)  
12 (19) 8 (17) 4 (22) 
Contralateral metal-on-
metal hip bearing at revision 
(%) 
Total = 26 (41) 
19 (73) HR 
7 (27) THR 
Total = 21 (46) 
16 (76) HR 
5 (24) THR 
Total = 5 (28) 
3 (60) HR 
2 (40) THR 
Prosthesis revised (%)  BHR 32 (70) 
Corin McMinn 
11 (24) 
Conserve Plus 
2 (4) 
Other 1 (2) 
Corail / 
Pinnacle 
7 (39) 
Modular BHR 
6 (33) 
Other 5 (28) 
Median femoral component 
head size in millimetres 
(range) 
 46                 
(38-52) 
36                
(36-50) 
Mean time from primary 
arthroplasty to revision in 
years (range) 
5.5               
(1.1-13.8) 
5.8               
(1.1-13.8) 
4.7              
(1.7-11.6) 
Mean time from primary 
arthroplasty to symptoms in 
years (range) 
3.9                  
(0-13.6) 
4.1                 
(0-13.6) 
3.2                
(0-10.9) 
Mean time from symptoms 
to revision in years (range) 
1.6            
(0.02-7.2) 
1.7            
(0.02-7.2) 
1.6            
(0.14-5.4) 
Index metal-on-metal HR or 
THR performed at another 
institution (%) 
20               
(31) 
12                
(26) 
8                
(44) 
 
AVN = avascular necrosis of the femoral head; BHR = Birmingham Hip Resurfacing; 
DDH = developmental dysplasia of the hip; HR = hip resurfacing; NOF = neck of femur 
fracture; OA= Osteoarthritis; SUFE = slipped upper femoral epiphysis; THR = total hip 
replacement 
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5.3.2 Definition for adverse reaction to metal debris 
ARMD was originally described as an umbrella term which includes the presence of 
metallosis, pseudotumour, aseptic lymphocytic vasculitis associated lesions, and 
macroscopic tissue necrosis [36,41]. In the present study a diagnosis of ARMD was 
made if on review of both the clinical and histopathological information there were 
features compatible with those consistently reported in the literature. This included 
clinical evidence of periprosthetic joint effusions or solid masses, metallosis, 
macroscopic tissue necrosis or foreign body granulomas, and histopathological evidence 
of aseptic foreign body or phagocytic reactions, significant metal wear debris, 
lymphocytic reactions and tissue necrosis [114]. Three patients (three hips) were 
initially deemed eligible for inclusion but subsequently demonstrated evidence of 
infection from the samples sent at the time of revision surgery for microbiological and 
histopathological analysis. These three patients were excluded leaving a final cohort of 
64 MoM hips in 63 patients revised for ARMD.  
 
5.3.3 Data collection 
Cases of ARMD were identified from prospectively maintained clinical and 
histopathological databases. Data were collected from the institutional databases and 
patient case notes using a standard proforma. The pre-operative variables collected 
were: patient age and gender, any previous surgery on the ipsilateral hip, the indication 
for index MoM arthroplasty and components implanted, the presence of a contralateral 
MoM hip bearing, the institution at which the index arthroplasty was performed, the 
date of presentation with symptoms, radiological findings prior to revision (Chapter 
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2.3.4 and 3.3.5), and the date of revision. Acetabular component inclination was 
measured in each radiograph. The intra-operative variables were: the macroscopic 
features at revision, the specific components revised including the revision bearing 
used, and operative time. Data were also collected on relevant outcomes of interest 
following ARMD revision surgery (Chapter 5.3.6).           
 
5.3.4 Histopathological analysis 
All histopathological sections from the periprosthetic tissue of hips revised for ARMD 
were reviewed by two consultant histopathologists (PAR and VPS). Both were blinded 
to the clinical details and cellular pathology diagnostic reports in all cases. 
Categorisation was performed using previously described criteria [112]. On the basis of 
this review all cases were assigned to one of four histopathological categories: (1) no 
lymphocytic infiltrate; (2) diffuse lymphocytic infiltrate (with T cells but no 
aggregates); (3) lymphocyte aggregates containing T cells; (4) TLO structures 
containing both T and B cell aggregates.  
 
5.3.5 Follow-up after revision surgery  
Following revision patients were seen in the outpatient clinic at six-weeks, six-months, 
and one-year post-operatively. Thereafter review was according to clinical need, usually 
annually. All consultations included clinical examination, anteroposterior pelvic 
radiographs, and completion of the OHS questionnaire (Appendix 2) [65]. All 
radiographs were analysed for signs suggestive of implant failure as previously 
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described (Chapter 2.3.4 and 3.3.5). The OHS questionnaire was scored as described 
(Chapter 2.3.3).  
 
Patients not reviewed in clinic within 12 months of study commencement were sent a 
postal questionnaire to determine their OHS and identify whether they had any further 
surgery on the revised hip (Appendix 1). Patients failing to respond to the postal 
questionnaire were subsequently contacted by telephone to complete data collection. All 
deaths were recorded and assessed as previously described (Chapter 2.3.2).  
 
5.3.6 Outcomes of interest   
The defined clinical outcomes of interest following revision hip arthroplasty for ARMD 
were: (1) any complication related to revision surgery, (2) re-revision surgery, and (3) 
post-revision OHS.  
 
5.3.7 Statistical analysis  
All statistical analysis was performed using the program R [73]. Cumulative implant 
survival analysis was performed as described (Chapter 2.3.5). The endpoint for survival 
analysis was re-revision surgery, defined as removal or exchange of any component. A 
Cox-proportional hazards model was used to determine the affect of (1) 
histopathological category, and (2) patients with a contralateral MoM bearing, on the 
risk of re-revision surgery. 
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Pre-operative and intra-operative variables were analysed in relation to the three 
outcomes of interest (Chapter 5.3.6). Chi-squared test with Yeates’s correction was used 
to compare proportions between single variables, though in instances where less than 
five hips were in any subgroup a Fisher’s exact test was performed instead. Unpaired t-
tests were used for analysing numerical data. Mood’s test was used to compare medians 
for the OHS data. The level of significance was set at 95% (p<0.05) and CIs were also 
at the 95% level.   
 
5.4 Results  
 
5.4.1 Clinical outcomes following revision  
No patients were lost to follow-up. At a mean follow-up time from revision of 4.5 years 
(range 1.0-14.6 years) there have been 13 (20.3%) complications related to surgery. The 
five complications not requiring re-revision were: superficial wound infection (n=1; 
treated with oral antibiotics), deep vein thrombosis (n=1; treated with oral 
anticoagulation), permanent sciatic nerve palsy (n=1), dislocation (n=1; 4.5 months after 
revision treated by closed reduction with no subsequent dislocations), and hip 
haematoma (n=1; resolved following conservative treatment).  
 
Eight hips (12.5%) required re-revision with all further surgery performed at this 
institution (Table 5.2). In addition four patients (four hips) died at a median time of 2.7 
years from revision arthroplasty. None of the deaths were related to surgery and no 
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patient had undergone re-revision surgery. The cumulative survival for revision hip 
arthroplasty performed for ARMD was 87.9% (95% CI 78.9%-98.0%) at 5-years (19 
hips at risk) and 83.0% (95% CI 71.0%-97.1%) at 10-years (4 hips at risk). At the time 
of writing, no other patients in this cohort were awaiting re-revision surgery.  
 
Table 5.2 Details of 8 hips undergoing re-revision during follow-up  
Age / 
Sex / 
Implant 
Femoral 
head 
size 
(mm) 
Time to 
re-
revision 
(years) 
Indication for 
re-revision 
 
Re-revision 
performed 
 
Outcome after 
re-revision 
48F 
THR 
(MoP) 
32 0.27 Recurrent 
dislocation 
Head + liner 
(constrained) 
exchange 
(MoP) 
No 
complications 
at 4.3 yr 
65F 
THR 
(OxP) 
36 0.31 Deep infection Washout 
with head + 
liner 
exchange 
(OxP) 
Girdlestone at 
0.5 yr due to 
persistent 
infection 
65F 
THR 
(MoM) 
42 0.83 Recurrent 
dislocation 
Head + liner 
(constrained) 
exchange 
(MoP) 
No 
complications 
at 5.9 yr 
40M 
HR 
(MoM) 
50 1.3 Component 
mismatch 
causing 
impingement 
Revised to 
uncemented 
THR (MoM) 
No 
complications 
at 0.5 yr with 
normal blood 
metal ion levels 
56F 
HR 
(MoM) 
46 2.0 Unexplained 
pain (no 
significant 
findings at 
revision to 
explain pain 
and normal 
histology) 
 
Revised to 
uncemented 
THR (CoC) 
No 
complications 
at 1.3 yr 
38F 
HR 
(MoM) 
50 4.0 Recurrent 
ARMD 
Revised to 
uncemented 
THR (OxP) 
No 
complications 
at 0.5 yr 
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70M 
THR 
(MoM) 
48 6.4 Recurrent 
ARMD 
Revised to 
uncemented 
THR (CoP) 
No 
complications 
at 0.5 yr 
53F 
THR 
(MoP) 
28 11.4 Aseptic 
acetabular 
loosening 
Revised to 
uncemented 
cup and 
cemented 
stem (MoP) 
+ femoral 
head 
allograft 
No 
complications 
at 1.9 yr 
 
ARMD = adverse reaction to metal debris; CoC = ceramic-on-ceramic; CoP = ceramic-
on-polyethylene; F = female; HR = hip resurfacing; M = male; MoM = metal-on-metal; 
MoP = metal-on-polyethylene; OA = osteoarthritis; OxP = oxinium-on-polyethylene; 
THR = total hip replacement 
 
Excluding hips undergoing re-revision (n=8) the median OHS in patients revised for 
ARMD at latest follow-up was 18.8% (IQR 7.8%-48.3%). This equates to a median 
OHS of 39.0/48 (IQR 24.8/48-44.3/48). Excluding re-revisions the mean acetabular 
component inclination in the remaining 56 hips was 45.1° (range 31.1°-57.1°) at latest 
follow-up with no change in these angles from the initial post-revision radiographs. 
Three hips had evidence of non-progressive acetabular radiolucencies in zone 2 
following ARMD revision. There were no femoral component radiolucencies observed. 
In addition there was no evidence of neck narrowing or femoral component loosening in 
the three HRs which underwent acetabular only revisions, therefore retaining the 
original femoral resurfacing component.  
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5.4.2 Factors predictive of outcomes following revision 
The analyses of pre-operative and intra-operative factors and their affect on clinical 
outcomes following ARMD revision surgery are detailed in Table 5.3. 
 
Table 5.3 Affect of pre-operative and intra-operative factors on clinical outcomes 
following revision surgery for adverse reaction to metal debris 
 
   Complications Re-revision  
  Whole 
cohort 
(n=64) 
Hips without 
complications 
(n=51) 
Hips with 
complications 
(n=13) 
P 
value 
Hips 
not 
re-
revised 
(n=56) 
Hips 
re-
revised 
(n=8) 
P 
value 
Pre-
operative 
factors 
        
Gender F (%) 46 (72) 35 (69) 11 (85) 0.424 40 (71) 6 (75) 1.0 
M (%) 18 (28) 16 (31) 2 (15)  16 (29) 2 (25) 
Mean age at 
revision  
Years 
(range) 
57.8 
(31.0-
78.8) 
59.3  
(31.0-78.8) 
52.2  
(34.2-66.9) 
0.171 58.8 
(31.0-
78.8) 
 
51.1 
(34.2-
64.6) 
0.192 
Type of hip 
arthroplasty 
HR (%) 
 
THR (%) 
46 (72) 
 
18 (28) 
35 (69) 
 
16 (31) 
11 (85) 
 
2 (15) 
0.480 39 (70) 
 
17 (30) 
 
7 (88) 
 
1 (12) 
0.574 
Previous 
surgery on  
ipsilateral 
hip 
Number 
(%) 
12 (19) 8 (16) 4 (31) 0.333 9 (16) 
 
3 (38) 0.398 
Presence of 
contralateral 
metal-on-
metal hip 
bearing at 
revision 
Number 
(%) 
26 (41) 23 (45) 3 (23) 0.260 25 (45) 1 (13) 
 
0.178 
Mean time 
from index 
arthroplasty 
to 
symptoms* 
Years 
(range) 
3.9  
(0-
13.6) 
4.1  
(0-13.6) 
3.1  
(0.1-13.0) 
0.513 4.2  
(0-
13.6) 
1.2  
(0.1-
6.8) 
 
0.260 
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Mean time 
from 
symptoms to 
revision 
Years 
(range) 
1.6 
(0.02-
7.2) 
1.5  
(0-6.1) 
2.3  
(0.1-7.2) 
0.513 1.5  
(0-6.1) 
2.6  
(0.1-
7.2) 
 
0.260 
Index metal-
on-metal HR 
or THR 
performed at 
another 
institution 
(%) 
Number 
(%) 
20 (31) 17 (33) 
 
3 (23) 0.706 17 (30) 3 (38) 
 
1.0 
Radiological 
factors 
        
Mean 
acetabular 
component 
inclination 
Degrees 
(range) 
49.9 
(23.6-
75.0) 
50.0  
(23.6-75.0) 
49.4  
(30.6-67.0) 
0.704 49.7 
(23.6-
75.0) 
 
51.2 
(30.6-
67.0) 
0.692 
Loose stem  Number 
(%) 
16 (25) 13 (25) 3 (23) 1.0 14 (25) 2 (25) 1.0 
Loose cup Number 
(%) 
13 (20) 11 (22) 2 (15) 0.410 12 (21) 1 (13) 0.272 
Femoral 
neck 
thinning in 
HRs 
Number 
(%) 
12 (19) 10 (20) 2 (15) 1.0 11 (20) 1 (13) 1.0 
         
Intra-
operative 
factors 
        
Histo-
pathological 
category  
 
        
No 
lymphocytic 
infiltrate 
 
Number 
(%) 
13 (20) 10 (20) 
 
3 (23) 1.0 
 
11 (20) 
 
2 (25) 1.0 
Diffuse 
lymphocytic 
infiltrate 
Number 
(%) 
26 (41) 19 (37) 7 (54) 0.441 21 (38) 5 (63) 0.336 
Lymphocyte 
aggregates 
containing T 
cells  
 
Number 
(%) 
7 (11) 5 (10) 2 (15) 0.938 7 (13) 0 (0) 0.650 
Tertiary 
lymphoid 
organ 
structures 
Number 
(%) 
18 (28) 17 (33) 
 
1 (8) 0.136 17 (30) 
 
1 (13) 0.528 
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Mean 
operation 
time  
Minutes 
(range) 
91  
(40-
185) 
91  
(45-165) 
 
90  
(40-185) 
0.241 90  
(40-
165) 
 
98  
(60-
185) 
0.855 
         
Revision 
performed 
** 
 
        
Acetabular 
and femoral 
components  
Number 
(%) 
42 (66) 36 (71) 
 
6 (46) 0.272 39 (70) 3 (38) 0.323 
Acetabulum 
only 
 
 
Number 
(%) 
11 (17) 7 (14) 
 
4 (31) 0.322 8 (14) 
 
3 (38) 0.734 
Femoral 
component 
only 
Number 
(%) 
6 (9) 4 (8) 2 (15) 0.410 4 (7) 2 (25) 0.548 
         
Bearing 
implanted 
 
 
 
        
Metal-on-
polyethylene 
 
Number 
(%) 
32 (50) 28 (55) 4 (31) 0.196 30 (54) 2 (25) 0.376 
Metal-on-
metal 
 
Number 
(%) 
16 (25) 10 (20) 
 
6 (46) 0.102 11 (20) 5 (63) 0.046 
Ceramic-on-
polyethylene 
 
 
Number 
(%) 
8 (13) 8 (16) 
 
0 (0) 0.441 8 (14) 0 (0) 0.693 
Oxinium-on-
polyethylene  
 
 
Number 
(%) 
6 (9) 
 
 
3 (6) 3 (23) 0.410 5 (9) 1 (13) 1.0 
Ceramic-on-
ceramic 
Number 
(%) 
2 (3) 2 (4) 0 (0) 1.0 2 (4) 0 (0) 1.0 
         
Intra-
operative 
findings 
        
Metallosis Number 
(%) 
31 (48) 25 (49) 
 
6 (46) 0.854 27 (48) 4 (50) 0.925 
Peri-
prosthetic 
effusion*** 
Number 
(%) 
24 (38) 20 (39) 
 
4 (31) 0.438 
 
23 (41) 1 (13) 0.179 
Osteolysis Number 
(%) 
21 (33) 16 (31) 5 (38) 0.627 18 (32) 3 (38) 0.763 
Loose cup Number 
(%) 
18 (28) 16 (31) 
 
2 (15) 0.424 
 
17 (30) 1 (13) 0.528 
Soft-tissue 
damage 
Number 
(%) 
14 (22) 11 (22) 3 (23) 1.0 12 (21) 
 
2 (25) 1.0 
Foreign 
body 
granuloma 
Number 
(%) 
12 (19) 10 (20) 2 (15) 1.0 11 (20) 1 (13) 1.0 
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Loose stem Number 
(%) 
7 (11) 6 (12) 
 
1 (8) 1.0 7 (13) 0 (0) 0.650 
Fracture Number 
(%) 
5 (8) 4 (8) 
 
1 (8) 1.0 4 (7) 1 (13) 1.0 
Infection 
 
Number 
(%) 
5 (8) 
 
4 (8) 1 (8) 1.0 5 (9) 0 (0) 0.860 
Tissue 
necrosis 
Number 
(%) 
2 (3) 1 (2) 
 
1 (8) 0.191 2 (4) 
 
0 (0) 0.823 
 
F = female; HR = hip resurfacing; M = male; THR = total hip replacement 
*2 hips revised were asymptomatic 
**The remaining 5 hips initially underwent a first stage revision. They all had no 
histopathological or microbiological evidence of infection and subsequently all 
underwent revision to metal-on-polyethylene bearings. 
***Includes effusions on pre-operative imaging 
 
5.4.2.1 Pre-operative predictive factors 
There was no difference in the risk of re-revision between patients with unilateral and 
bilateral MoM hip bearings (p=0.178). No other pre-operative factors significantly 
affected the risk of complications or re-revision following ARMD revision (Table 5.3). 
No pre-operative factor significantly affected the absolute post-revision OHS (p-values 
ranged from 0.110-0.993 for the variables listed in Table 5.3). 
 
5.4.2.2 Intra-operative predictive factors 
The choice of revision bearing was the only intra-operative factor which predicted the 
risk of re-revision. Patients retaining MoM bearings were significantly more likely to 
require re-revision than those revised to different articulations (p=0.046). No intra-
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operative factor significantly affected the absolute post-revision OHS (p-values ranged 
from 0.090-0.939 for the variables listed in Table 5.3). 
 
Of the 64 ARMD revisions, 16 (25%) continued with a MoM bearing. All 16 hips were 
initially MoM HRs and were revised for persistent pain with or without cup 
malposition. As these 16 revisions were performed before ARMD was described as a 
clinical entity, no patient had pre-revision blood metal ions measured. Patients either 
underwent an acetabular component revision (n=6) or revision to a large diameter 
stemmed MoM THR (n=10). The 16 hips were subsequently classified as revised for 
ARMD based on the recorded intra-operative and histopathological findings.  
 
Five of the 16 hips (31%) retaining a MoM bearing have been re-revised (Table 5.2) and 
two patients (two hips) have died. The median OHS at latest follow-up for the nine 
patients with a MoM hip in-situ was 14.6% (IQR 4.2%-50.0%) which equates to 
41.0/48 (IQR 24.0/48-46.0/48). Median blood cobalt and chromium concentrations were 
6.1 µg/l (IQR 3.4 µg/l-8.2 µg/l) and 4.7 µg/l (IQR 3.8 µg/l-5.5 µg/l) respectively. Four 
of these nine MoM hips have bilateral MoM hip bearings and these are the four patients 
with the highest blood metal ion concentrations. None of these patients have 
demonstrated ARMD lesions on cross-sectional imaging, however all remain under 
regular clinical surveillance.  
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5.4.2.3 Histopathological response 
No significant difference was demonstrated in the risk of re-revision in patients with 
TLO structures (n=18) compared to those with non-TLO responses (n=46) (p=0.436). 
An additional model including the four histopathological categories as separate 
covariates (no lymphocytic infiltrate vs. diffuse lymphocytic infiltrate vs. lymphocyte 
aggregates containing T cells vs. TLOs) was similarly not significant (p=0.879). The 
post-operative absolute OHS was not significantly different between histopathological 
categories. 
 
5.4.2.4 Subgroup analysis 
Given 5 of the 8 re-revisions performed were in ARMD patients retaining a MoM hip 
bearing, it is possible that including the 16 hips revised to MoM bearings in the analysis 
could influence the results. Therefore a subgroup analysis (containing 48 MoM hips 
revised for ARMD with 3 re-revisions) was performed which excluded these 16 MoM 
hips.  
 
The cumulative survival for revision hip arthroplasty performed for ARMD in this 
subgroup was 91.0% (95% CI 77.0%-100%) at 5-years (11 hips at risk). Further 
analysis demonstrated there were no significant pre-operative or intra-operative 
variables predictive of clinical outcomes following ARMD revision (for the variables 
listed in Table 5.3, p-values ranged from 0.105-1.00 for complications and from 0.070-
1.00 for re-revision). Cox-proportional hazards models performed in the whole cohort 
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(n=64) were repeated for this subgroup (n=48). However in all instances the models 
were unstable due to only three re-revisions occurring during follow-up.  
 
5.5 Discussion 
Few studies have reported on outcomes following revision of MoM hip bearings for 
ARMD with most involving small cohorts limited by short-term follow-up (Chapter 4). 
The present study contributes to the literature by reporting clinical outcomes following 
64 ARMD revisions at a mean 4.5 year follow-up. This study is also the first to attempt 
to support clinical decision-making in the management of ARMD patients by 
comprehensively examining factors available to clinicians around the time of revision. 
 
Complication (20.3%) and re-revision rates (12.5%) in the present study are  
comparable to other studies reporting outcomes of revised ARMD hips (complication 
rates 4%-68% and re-revision rates 3%-38%) with similar indications for performing re-
revisions [46,58,101-104]. One previous study had a longer follow-up time (61 months) 
and a larger cohort (90 hips) than the present report, with this study reporting the best 
clinical outcomes following ARMD revision [104]. These more promising results may 
be related to the performance of single component HR revisions which were associated 
with less surgical morbidity and shorter operative times [104]. Five-year survival for 
ARMD revision was 87.9% in the present study with no known radiological failures. 
Although these results may be considered acceptable after THR revision, they are less 
favourable compared to results for HR revisions performed for other indications [105-
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107]. It is important surgeons are aware of the expected outcomes when counselling 
patients prior to ARMD revision surgery.  
 
Functional outcomes were satisfactory in this series (median OHS 18.8% or 39.0/48) 
and comparable to our historical results for primary THR (median OHS 14.6% or 
41.0/48) [67]. An earlier study reported significantly worse clinical and functional 
outcomes in HRs revised for pseudotumour compared to matched HRs revised for other 
indications and primary THR patients [46]. Liddle et al. also observed inferior 
outcomes in patients revised with solid pseudotumours [58]. In contrast, studies not 
observing such significant soft-tissue destruction at ARMD revision have reported more 
favourable outcomes [102,104], with one study finding the presence of soft-tissue fluid 
collections did not affect outcomes following revision [102]. The present study 
similarly failed to demonstrate worse outcomes in the presence of periprosthetic 
effusions, osteolysis, metallosis, soft-tissue damage, and tissue necrosis.   
 
Contrary to the study hypothesis, ARMD patients with TLO structures did not have 
significantly worse outcomes following revision compared to patients revised with other 
histopathological responses. This remained the same when all four histopathological 
categories were analysed separately (rather than TLO vs. non-TLO hips). This 
additional analysis was performed to determine if there were any differences in clinical 
behaviour between categories. Therefore despite TLO structures observed in revised 
ARMD hips appearing similar histologically to those seen in other autoimmune 
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conditions [112], the clinical behaviour of these TLO structures appears to be different 
to that expected. 
 
Retention of a MoM bearing was significantly more likely to require re-revision in this 
series than ARMD hips revised to non-MoM articulations. This was consistent with the 
study hypothesis that the persistence of MoM bearings following ARMD revision 
would adversely affect clinical outcomes. Some authors have observed good survival in 
patients receiving MoM bearings for ARMD [115]. However, most studies [39,58,104] 
support the present findings that MoM bearings are associated with higher re-revision 
rates. It is suspected the persistence of a MoM bearing provides a potential source of 
metal wear debris which perpetuates local tissue reactions. A recent study recommended 
revision of MoM hips for any indication should always include both sides of the bearing 
surface and result in a non-MoM bearing couple [58]. The present study observations 
support this recommendation. 
 
The ARMD hips revised to MoM articulations were performed early in this series 
before ARMD was an established clinical entity [35,36,41]. The relevance of 
exchanging the articulating surfaces is highlighted by the fact that two of eight re-
revisions performed in this series were for recurrent ARMD in which a MoM bearing 
was retained at the initial ARMD revision with no resolution of symptoms until the hips 
were re-revised to non-MoM articulations (Table 5.2). The remaining patients in this 
series with MoM hips in-situ are asymptomatic with good functional outcomes. 
Although the median blood cobalt concentration is raised in this subgroup, four patients 
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have bilateral MoM hip bearings with no ARMD lesions demonstrated on cross-
sectional imaging. However these patients remain under regular clinical surveillance. 
Given that ARMD recurrence has been documented in patients revised to a MoP 
bearing [103], it is important to consider this condition in patients with MoP bearings 
not progressing as expected following ARMD revision. Of the 32 hips revised to MoP 
bearings, 28 remain in-situ (2 re-revisions and 2 deaths). There have been no 
complications in this subgroup, with no concerns about ARMD recurrence at latest 
follow-up (median OHS 25%). However, it is recognised these patients have not 
routinely undergone blood metal ion sampling and cross-sectional imaging which are 
required to diagnose ARMD recurrence. 
 
Contralateral MoM hip bearings did not adversely affect outcomes following ARMD 
revision which was contrary to the study hypothesis. These findings are at variance with 
previous case reports demonstrating patients with bilateral MoM bearings can develop 
bilateral ARMD requiring revision surgery, with suggestion that a type IV immune 
response is responsible for these bilateral failures which develop after the implantation 
of the second MoM hip [116,117].  
 
This study has some recognised limitations.  As a retrospective study, it was subject to 
limitations such as data collection from the operative notes being dependent on the 
accuracy and terminology used by the recording individual. In addition some important 
pre-revision data were not available for analysis, namely acetabular component 
anteversion, blood metal ion concentrations, and OHSs, the latter of which would have 
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provided an assessment of change in function over time following revision surgery. It 
was also not routine practice at this centre to perform forensic analysis of explanted 
bearings which would have allowed an assessment of component wear to be made. 
Finally, although this case series is relatively large compared to previous studies 
(Chapter 4) it is recognised there was inadequate statistical power for some of the 
comparisons made. However obtaining larger patient cohorts would require a large 
multi-centre study with registry data not sufficient to answer the questions posed given 
the limited data set collected on each patient.   
 
In conclusion, the present study demonstrated the short-term morbidity in a large cohort 
of patients undergoing ARMD revision at a single specialist centre was comparable to 
previous reports. Although revision to a MoM bearing provided good functional 
outcomes in non-revised patients, there was an association with higher re-revision rates 
when using this articulation in ARMD revision surgery. It is therefore recommended 
caution is exercised in the choice of bearing when revising MoM hip arthroplasties for 
ARMD.  
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CHAPTER 6 
CONCLUSIONS  
 
6.1 The role of metal-on-metal hip arthroplasty 
The use of MoM bearings for hip arthroplasty in young and active patients has been an 
attractive concept due to low wear rates [11], greater range of hip motion, and a lower 
risk of dislocation [12,13]. Furthermore MoM HR has additional benefits including 
femoral bone conservation permitting easier revision in cases of HR failure, more 
normal gait patterns, and increased activity levels compared to conventional THR [118]. 
Recently the role of MoM hip arthroplasty has been questioned in light of ARMD and 
the high failure rates of certain MoM hip implants [35-38,41,55,119]. The present 
research aimed to determine the medium-term to long-term clinical outcomes following 
MoM HR and THR (Chapters 2 and 3). 
 
Although a number of studies reported promising early clinical results following 
modern MoM HR [25-32], one of the designing surgeons acknowledged caution was 
needed with HR until long-term results were available [26]. Since these early reports it 
has become increasingly apparent that outcomes following HR are dependent on various 
patient, surgeon, and implant factors [13]. When these factors are optimised excellent 
long-term survival and functional outcomes can be achieved with MoM HR in young 
and active patients with hip arthritis (Chapter 2). This subgroup of patients has 
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traditionally experienced unsatisfactory long-term results with conventional THR [9,10, 
59,60]. 
 
What has also become clear over recent years is that the indications for MoM HR are 
actually narrower than originally described [62]. Following a review of outcomes in 
3095 BHRs McMinn et al. observed inferior 10-year survivorship in patients with a pre-
operative diagnosis of developmental dysplasia of the hip (94%) and avascular necrosis 
of the femoral head (93%) compared to all other indications for HR (98%) [51]. These 
findings have recently been confirmed at 15-years following BHR, leading the authors 
to modify their indications for performing HR [51,120]. Although the present research 
confirms the promising outcomes following BHR extend into the second decade (94.1% 
survival at 14-years) the best results were achieved in patients with primary 
osteoarthritis (Chapter 2). Nearly half of all revised hips were in patients with diagnoses 
other than primary osteoarthritis, although only 32% of all BHRs were implanted for 
these indications (Chapter 2). On the basis of the results obtained by experienced 
surgeons when using the BHR for indications other than primary osteoarthritis and the 
findings that HRs performed for hip dysplasia are associated with an increased risk of 
ARMD [44], it is recommended arthroplasty options other than HR are considered for 
treating this subgroup of patients.   
 
The BHR is one of the most commonly used MoM HR devices worldwide [61]. Its 
continued use is supported by reports from independent centres demonstrating good 10-
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year survival of up to 94.5% (total of 1487 BHRs between the five studies) [52-54, 
121,122]. The Conserve Plus (Wright Medical, Arlington, Tennessee, United States of 
America) is the only other HR device that has an established track record with the 
promising 10-year survivorship from the designing surgeon (88.5%) [123] supported by 
a recent independent report [124]. Contrary to the findings from designing HR surgeons 
[50,51,90,120,123], some reports from independent centres have suggested against 
performing HR in female patients [52,54]. When performed by the two designing 
surgeons BHR survival in females was 91.2% at 14-years (109 hips with primary 
osteoarthritis) (Chapter 2) and 91.5% at 15-years (335 hips with all diagnoses) [120]. 
The 10-year survival of BHRs implanted in females at independent centres ranges from 
73.9% to 89.1% [52-54,121,122]. As these independent results in females are inferior to 
both the proposed revision rates from NICE for continued implant usage [80] and the 
results achieved with conventional THR in this patient subgroup [2], it is recommended 
HR is not performed in females at independent centres.   
 
In light of the present evidence regarding the medium-term to long-term outcomes 
following MoM HR it is possible to define the indications for continued use. The 
implant must either be a BHR or Conserve Plus device. The surgeon must have 
sufficient experience with implanting HRs given the procedure is more technically 
demanding than conventional THR [76]. The patient must meet the previously 
described indications for HR (young and active, with adequate proximal femoral bone 
quality, and no renal function impairment) [62], but also have primary osteoarthritis and 
adequate femoral anatomy to allow the use of head sizes typically above 46 mm. 
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Surgeons at independent centres should only perform HR on male patients whilst 
designing surgeons may perform HR on both genders meeting the aforementioned 
selection criteria. On occasions experienced surgeons may wish to consider older 
patients for HR provided they are active and meet all other proposed indications. This is 
because chronological age was not originally cited as an absolute contraindication to 
HR [62], with good medium-term to long-term outcomes reported by designing 
surgeons in patients aged over 60-years [120,125].  
 
Finally all patients considered appropriate for MoM HR must undergo thorough pre-
operative counselling. This should include explanation of: (1) the unique complications 
of HR (such as femoral neck fracture), (2) the potential for wear related complications 
associated with MoM bearings requiring investigation with blood metal ion sampling 
and cross-sectional imaging with revision surgery needed in certain cases, and (3) the 
unknown potential long-term adverse risks of systemic metal ion exposure. Such 
comprehensive counselling will allow patients suitable for MoM HR to make informed 
decisions regarding their treatment.    
    
By contrast there is sufficient evidence to suggest MoM THRs should not be implanted 
in the future. The NJR of England, Wales, and Northern Ireland reported cumulative 8-
year survival of all uncemented MoM THRs of 84.5%, however for different implant 
designs this ranged from 56.7% to 88.9% [2]. Although the 8-year survival of 88.9% 
from the present research (Chapter 3) appears favourable compared to other MoM THR 
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designs, it is below NICE recommendations for continued implant usage [80]. The 
suboptimal outcomes of all modern large-diameter MoM THRs suggests although the 
concept is fundamentally flawed variations in implant design between devices can 
significantly affect survivorship. Further analysis of registry data demonstrated MoM 
THRs have increasing failure rates with larger femoral head sizes and significantly 
inferior survivorship compared to MoP and CoC THR [55]. The authors therefore 
recommended against the future use of stemmed MoM THRs [55]. Given the poor 
outcomes of modern MoM THR it is advised all patients with these devices remain 
under regular clinical surveillance according to published protocols [48]. It is suggested 
more frequent surveillance may be needed in patients with the poorest performing 
implant designs with surgeons also having a lower threshold for revision surgery in 
these cases.   
 
Given the only future role of MoM hip arthroplasty is for a subgroup of patients 
meeting the refined selection criteria for HR, it follows that consideration is needed 
regarding the type of THR patients who would have previously undergone MoM hip 
arthroplasty should receive. Popular bearing surfaces include ceramic femoral heads 
with ceramic or highly cross-linked polyethylene liners or metal heads with highly 
cross-linked polyethylene liners. Although these THR bearing surfaces have promising 
outcomes at up to 10-years [78,79,126-128] they must be used with caution until long-
term results are established given late modes of failure may occur which could alter the 
indications for bearing usage. Recently, the use of large-diameter CoC bearings has 
been recommended in place of poorly performing MoM THRs [55]. However in light of 
concerns that taper junction failures seen in MoM articulations may occur in non-MoM 
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large-diameter THRs [129], the widespread usage of large femoral head sizes is not 
recommended in this time of uncertainty.  
 
Finally consideration should be given to modular THRs. A range of head-neck, neck-
stem, and mid-stem modular THR systems are available to treat patients with complex 
anatomy. Almost all of the 460,000 primary and revision THRs performed in the United 
States in 2011 involved head-neck modularity with up to 8% involving both head-neck 
and neck-stem or mid-stem modularity [130]. Metal ion release and corrosion may 
occur at these modular junctions resulting in ARMD, even when using non-MoM 
bearing surfaces [86,131-133]. Modular implants should therefore not be recommended 
for routine primary THR, with guidance regarding patient follow-up in light of ARMD 
recently published [134].               
 
6.2 Revision surgery for adverse reaction to metal debris  
In 2009 poor short-term clinical outcomes were reported following revision of MoM 
HRs for pseudotumours [46]. With the revision burden for ARMD associated with 
MoM hips continuing to increase [2,58,102] and more recent observations that ARMD 
can occur in modular THRs with non-MoM bearings [86,132,133], it is important 
surgeons are aware of the expected outcomes following ARMD revision. The present 
research aimed to determine the clinical outcomes following revision of MoM HRs and 
THRs for ARMD, and identify factors predictive of outcomes (Chapters 4 and 5). 
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A systematic review demonstrated few studies have been published on outcomes 
following ARMD revision, especially for large-diameter MoM THRs, with outcomes 
variable between studies (Chapter 4). To supplement current evidence, outcomes were 
assessed in 64 MoM hips revised for ARMD at one centre, with similar complication 
(20.3%) and re-revision rates (12.5%) observed to previous studies at a mean 4.5 year 
follow-up (Chapter 5). Comprehensive analysis of pre-operative and intra-operative 
factors predictive of outcome demonstrated only revision to another MoM bearing was 
associated with significantly higher re-revision rates (Chapter 5). It is therefore 
recommended non-MoM bearings are used when performing ARMD revisions. 
Although the work presented is the first to attempt to support clinical decision-making 
in managing ARMD patients it is recognised it was limited by inadequate statistical 
power. For the Cox-proportional hazards model assessing the affect of a contralateral 
MoM bearing on re-revision risk (Chapter 5.4.2.1), it is estimated a minimum of 210 
hips are needed in each group to have 80% statistical power (assuming an equal number 
of events in each group, an alpha of 0.05, and the null hypothesis that the hazard rates 
are equal). However such patient numbers can only be obtained in large multi-centre 
studies.  
 
In addition to the present research (Chapter 5), repeating the systematic review up until 
16th September 2014 with the same study inclusion criteria (Chapter 4.3.2) identified 
three further studies reporting outcomes following ARMD revision [135-137]. Su et al. 
assessed outcomes at a mean of 2.3 years following 55 HR revisions of which 22 were 
performed for ARMD or unexplained pain [135]. Short-term outcomes following 
revision were generally good, though patients revised for metal sensitivity and 
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unexplained pain had the poorest functional outcomes [135]. A more recent report of 35 
HRs revised for ARMD demonstrated significant improvement in functional outcomes 
by six-months post-revision, though outcomes were not related to the severity of the 
histopathological response [136]. The third study assessed outcomes following revision 
of 114 monoblock MoM THRs with 51% of these performed for ARMD [137]. By 
contrast to the HR studies [135,136], complication (20%) and re-revision rates (16%) 
were high at only a mean follow-up of 14 months with greater morbidity observed in 
older patients [137]. The only study identified in the initial systematic review reporting 
outcomes following MoM THR revision for ARMD [103] similarly reported high 
complication and re-revisions rates at short-term follow-up (Table 4.3). Therefore, it is 
suspected outcomes following MoM THR revision for ARMD are inferior to those 
following HR revision for ARMD. This may be due to modular THR junctions having 
the potential to produce wear debris and the challenges which can be associated with 
femoral component removal and reconstruction. However further studies are needed to 
assess this in more detail.             
 
There are two strategies which may reduce morbidity following ARMD revision. The 
first is considering all patients with MoM hips for early revision surgery. Previous 
recommendations for early surgical intervention were based on the premise that soft-
tissue destruction is time-dependent [13,46,48]. Studies reporting on patients with more 
severe soft-tissue destruction [46,58] observed poorer outcomes compared to those not 
reporting significant soft-tissue problems [102,104]. However applying a strategy of 
early revision universally is not advisable as little is known about the natural history of 
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ARMD [93,94]. Therefore patients with MoM hip bearings may never develop ARMD 
but could be unnecessarily subjected to further surgery which itself is not without risk. 
 
The second strategy to reduce morbidity following ARMD revision is to consider 
methods for reducing the risks of the main post-revision complications, namely 
dislocation, ARMD recurrence, and acetabular component loosening (Chapter 4). De 
Smet et al. observed a reduction in morbidity following HR revisions with the routine 
use of hip abduction braces and large non-metallic femoral heads [102]. However with 
concerns about taper wear with femoral head sizes over 36 mm it is recommended 36 
mm may provide the best option [92,103]. Dual-mobility cups provide another option 
for dislocation prevention though long-term results are needed [138,139]. ARMD 
recurrence can be minimised by thorough debridement of all macroscopic metal wear 
debris and exchange to non-MoM bearings. The former may require specialists in pelvic 
and soft-tissue reconstruction which highlights the importance of thorough pre-revision 
planning. The extent of bone loss needs to be considered when planning acetabular 
reconstruction with revision implants chosen accordingly. However, given some 
patients have extensive bone loss at revision, newer implants which achieve better 
fixation in such situations require development.    
 
6.3 Recommendations for future research 
Further long-term clinical studies are required in patients undergoing HR, especially 
from independent centres. These studies should include the BHR and Conserve Plus 
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devices given that these two implant designs have the best reported results to date and 
therefore have potential for future use. Establishing survival and functional outcomes at 
over 15-years follow-up will assist in refining patient selection for HR and also identify 
if late modes of implant failure differ from those following THR.  
 
Given the numerous reports relating to ARMD and MoM hip bearings it is 
recommended centres publish their outcomes following ARMD revision surgery, 
especially after MoM THR revision. It would be preferable to use a standard set of 
outcome measures in these reports such as those used in this systematic review (Chapter 
4.3.4). More uniform reporting of outcomes would allow meta-analysis to be performed 
in the future. This will provide the large cohort of ARMD revisions with sufficient 
statistical power to identify prognostic factors of outcome, and therefore define the 
thresholds for performing ARMD revision surgery. Arthroplasty surgeons would 
subsequently have an evidence based tool for clinical decision making in patients with 
MoM hip replacements.     
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APPENDIX 1 Further surgery questionnaire 
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APPENDIX 2 Oxford Hip Score questionnaire 
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APPENDIX 3 University of California, Los Angeles Activity Score 
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APPENDIX 4 Letter sent to patients with metal-on-metal THRs  
 
 
 
 
Date 
(Name and address) 
 
Dear (Patient), 
 
Re: Metal-on-Metal Total Hip Joint Replacements 
You may be aware of the recent media discussions about the safety of metal-on-metal hip 
replacements and resurfacings. 
One type of hip resurfacing, the DePuy ASR, has had a higher than anticipated failure rate and 
as a consequence was withdrawn from use in September 2010. This resurfacing has never been 
used at the Royal Orthopaedic Hospital. 
The Medicines and Healthcare Regulatory Authority (MHRA) has raised concerns regarding 
both metal on metal hip replacements and some resurfacings based on the poor results of some 
designs. Our records show that you have a DePuy Corail/Pinnacle total hip replacement. 
If you already have a follow-up outpatient appointment booked within the next three months, 
you do not need to take any further action. If you do not have a follow-up appointment in the 
next three months please complete the enclosed forms and return them in the pre-paid envelope.   
We will then make arrangements for you to have a blood test and updated x-ray and subsequent 
review appointment as appropriate. We are reviewing patients in accordance with national 
standards which have recently been changed to recommend an annual review and blood test. 
We are committed to providing the best possible service for our patients. If you have any 
questions or queries about your hip surgery, please use the comments box on the questionnaire 
and we will be happy to address your concerns.   
 
Yours sincerely 
 
Mr xxxx xxxx FRCS 
Individual surgeon 
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